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The overall goal of this thesis was to develop a dry powder delivery system for patients 
on mechanical ventilation. The studies were divided into two parts: the formulation development 
and the device design. The pulmonary system is an attractive route for drug delivery since the 
lungs have a large accessible surface area for treatment or drug absorption. For ventilated 
patients, inhaled drugs have to successfully navigate ventilator tubing and an endotracheal tube. 
Agglomerates of drug nanoparticles (also known as ‘NanoClusters’) are fine dry powder aerosols 
that were hypothesized to enable drug delivery through ventilator circuits.  
This Thesis systematically investigated formulations of NanoClusters and their aerosol 
performance in a conventional inhaler and a device designed for use during mechanical 
ventilation. These engineered powders of budesonide (NC-Bud) were delivered via a Monodose® 
inhaler or a novel device through commercial endotracheal tubes, and analyzed by cascade 
impaction. NC-Bud had a higher efficiency of aerosol delivery compared to micronized stock 
budesonide. The delivery efficiency was independent of ventilator parameters such as inspiration 
patterns, inspiration volumes, and inspiration flow rates. A novel device designed to fit directly 
to the ventilator and endotracheal tubing connections and the Monodose® inhaler showed the 
same efficiency of drug delivery. The new device combined with NanoCluster formulation 
technology, therefore, allowed convenient and efficient drug delivery through endotracheal 
tubes. 
Furthermore, itraconazole (ITZ), a triazole antifungal agent, was formulated as a 
NanoCluster powder via milling (top-down process) or precipitation (bottom-up process) without 
using any excipients. ITZ NanoClusters prepared by wet milling showed better aerosol 
performance compared to micronized stock ITZ and ITZ NanoClusters prepared by precipitation. 
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ITZ NanoClusters prepared by precipitation methods also showed an amorphous state while 
milled ITZ NanoClusters maintained the crystalline character. Overall, NanoClusters prepared by 
various processes represent a potential engineered drug particle approach for inhalation therapy 
since they provide effective aerosol properties and stability due to the crystalline state of the drug 
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1.1 Thesis goal, outline and specific aims 
 The overall goal of this work was to develop a dry powder delivery system for patients on 
mechanical ventilation. The studies were divided into two parts: the formulation development 
and the device design. NanoCluster technology was used for formulating inhaled drug powder. 
Budesonide, a potent glucocorticoid, was selected as a drug model. Inhaled budesonide has been 
used for treatment of asthma and COPD for a long time1-3. Budesonide could be a potent therapy 
for ventilated patients if delivered effectively. Because the endotracheal tube is a great barrier to 
successful delivery, in chapter 2, agglomerates of budesonide (Bud) nanoparticles (also known as 
‘NanoClusters’) were formulated and investigated when delivered through different kinds of 
tubes with negative pressure. Formulas with or without excipients were prepared and compared 
with micronizied stock budesonide and with the Pulmicort® Flexhaler powder (AstraZeneca LP, 
Wilmington, Delaware).  
The optimized formulation was tested on a mechanical ventilation system (chapter 3). 
The effect of ventilator parameters on drug powder performance was investigated. Furthermore, 
a novel device was designed to fit with the ventilator circuit. The performance of the novel 
device was compared to a modified Monodose® inhaler. The novel device was preferred to the 
Monodose® inhaler due to the convenience of connecting with the ventilator and endotracheal 
tubing while maintaining efficient aerosol delivery. NanoCluster technology combined with a 
new device may provide simple and effective drug delivery to ventilated patients.  
The success of NanoCluster technology on budesonide (drug model) led to a formulation 
of itraconazole NanoClusters (chapter 4). Itraconazole (ITZ) is a triazole antifungal agent that is 
used to treat fungal infections. It works by slowing the growth of fungi that cause infection. For 
treatment of fungal infections in the lungs, ITZ capsules are taken orally. However, ITZ can 
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show low and variable oral absorption due in part to variability in gastric conditions. A study 
reported the lung tissue concentration increased nearly 10 times when ITZ was administered by 
inhalation compared to the oral route4. Therefore, NanoCluster technology may offer effective 
drug formulation of ITZ for direct administration to the lungs of mechanically ventilated 
patients. 
1.2 Introduction 
Inhalation therapy has been used for treatment of respiratory disorders for a long time5,6. 
In ancient times, patients inhaled a variety of substances released from plants for medicinal 
proposes such as volatile gases from pines, vapors from heated Hyosycamus muticus, and smoke 
containing atropine from Atropa belladonna leaves7. For over half a century, inhalation therapy 
has been employed in mechanically ventilated patients. Although the ventilator was not 
originally designed for aerosolized medicine, various inhalers have been designed for use in 
ventilator-supported patients, especially drugs with poor oral bioavailability or local effect in 
lungs. Despite periodic successes, aerosolized therapies are often not successful due to 
ineffective and inconsistent aerosol delivery. The major barriers to success are aerosol-
generating devices appropriate for ventilator circuits and poor drug formulations that are not 
conducted through the ventilator circuit and endotracheal tube. To overcome these barriers and 
optimize aerosol delivery in patients, new aerosol technologies, formulations and devices are 
being designed.  
In the critical care setting, inhaled drugs are routinely delivered to ventilated patients in 
the form of wet aerosols via nebulizers or pressurized metered-dose inhalers (pMDI). These wet 
aerosols suffer from rain out, condensing in the ventilator circuit and the endotracheal tube 
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leading to poor delivery8. Thus, dry powder aerosols are being investigated as alternative 
formulations. In general, dry powder formulations are delivered direct-to-mouth via dry powder 
inhalers (DPIs). None of the DPIs on the market, however, have been designed for use with 
ventilator systems. The design of inhalers is important for developing drug delivery systems 
appropriate for mechanical ventilation. Such DPIs should be designed to optimize drug delivery 
with typical mechanical ventilation settings. Sufficient shear forces should be generated to break 
up agglomerated powders. Moreover, the design of the inhaler should allow direct connection 
with minimal adapters for easier use. In the development of new drug delivery technologies for 
patients on mechanical ventilation, both particle engineering and inhaler designs play a 
significant role in the delivery of dry powders. This review will summarize the state of the art for 
aerosol delivery to patients on mechanical ventilation with special emphasis on emerging 
opportunities for dry powder aerosols.  
1.3 The lungs as a delivery target 
The respiratory tract is divided into the upper and the lower airways. The upper airway 
begins at the nasal or mouth cavity and travels into the larynx, and the lower airway begins at the 
larynx and travels to the alveoli (Figure 1.1). When inspiration occurs, air passes through the 
conducting zone (from the trachea down to the terminal bronchioles, the smallest airways 
without alveoli) to the respiratory zone with respiratory bronchioles and alveoli, where gas 
exchanges through alveolar walls9.  




Figure 1.1 Structure of the respiratory system (reprint with permission).10 
 
From the trachea, a series of branching airways become more numerous and smaller in 
diameter down to the alveolar region. The branching pattern of the lungs produces a large surface 
area within a small volume. The diameter of the airways decreases from about 1.8 cm in the 
trachea to about 300 µm in alveolar sacs with a corresponding increase in the surface area of the 
airways11. The total surface area of the lungs is approximately 140 square meters in an adult 
human12. There are around 500 million alveoli in the human lungs with a large surface of more 
than 100 square meters6,13. Thus, the lungs generate large surfaces for gas diffusion although 
their volume is only about 4 liters.  Lung epithelium becomes thinner as the airways decrease in 
diameter, reaching a thickness less than 0.1 µm in the alveoli region6,14. The large surface area 
combined with the thin epithelium provides advantages in both local and systemic delivery. 
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1.3.1 The lungs as a target for local drug delivery 
Inhaled medications have been available for treatment of diseases such as asthma and 
chronic obstructive pulmonary disease (COPD) for many years. More than 65 inhaled products 
of more than 20 active pharmaceutical ingredients (API) are on the market15-17. For treatment of 
respiratory diseases, inhalation has many advantages over the systemic route. Pulmonary drug 
delivery can provide high drug concentrations at the site of disease with minimized systemic 
exposure and side effects compared to the oral route. If attempting to deliver drugs systemically, 
inhalation can also eliminate barriers such as poor gastrointestinal absorption and first-pass 
metabolism.  
The efficiency of drug treatment, however, depends on the distribution of drug aerosols 
within the lungs. For instance, a study showed that histamine aerosols deposited in the 
conducting airways increase airways obstructions more than histamine aerosols deposited 
diffusely, because histamine receptors were predominantly in the central airways18. Similarly, 
other studies suggested that the site of drug deposition was important to maximize the 
therapeutic response15,19,20. For example, β2-agonist deposited in the conducting airways is more 
important in moderating the bronchodilator response than β2-agonist deposited into the alveolar 
region19. Ipratropium bromide (an anticholinergic drug used for the treatment of chronic 
obstructive pulmonary disease and acute asthma) needs to be delivered to the conducting airways 
to produce therapeutic effects due to the presence of receptors in the smooth muscle of the 
bronchi21,22. Inhaled corticosteroids act through the glucocorticoid receptor in bronchial 
epithelial cells20,23, so the target area of corticosteroid deposition is also in the conducting 
airways. A large portion of corticosteroid deposited in the alveolar region may not achieve the 
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desired efficacy. On the other hand, some lung infections require the antibiotic to be evenly 
distributed throughout the lungs or primarily in the peripheral region15. Although the target site 
for most respiratory diseases is in the conducting airways, the optimal site of deposition for 
aerosolized antibiotics depends on the indication. 
1.3.2 The lungs as a target for systemic drug delivery 
Besides local diseases, inhalation has been recently studied for treatment of systemic 
diseases such as diabetes24, migraines25,26 and seizures27. Pulmonary drug delivery offers several 
advantages over other routes of administration for delivery of therapeutic drugs into the systemic 
circulation. It has no 1st pass effect when drugs are administered via pulmonary drug delivery. As 
discussed earlier, the lungs have a large absorptive surface area and a highly permeable 
membrane of thin epithelium in the alveolar region. The alveolar membrane is an ideal site for 
exchange between the blood compartment and the external environment. Pulmonary drug 
delivery can provide rapid absorption and increased bioavailability of drug molecules compared 
to oral administration. It is suitable for a wide range of substances from small molecules to large 
proteins, especially for large molecules with low absorption rates14.   
Generally, macromolecules such as proteins cannot be administered orally because they 
are digested and not absorbed into the bloodstream due to enzyme activity and the absence of an 
appropriate transcellular transport pathway. Administration of these kinds of molecules is 
primarily intravenous or subcutaneous injection. Inhalation, however, can increase 
bioavailability of peptides and proteins 10 to 200 times compared to other routes28. Inhaled 
insulin (Exubera) was approved by the FDA and the European Medicines Agency29. Inhaled 
insulin showed similar pharmacokinetic and intra-individual variability as injectable insulin30. It 
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provided noninvasive “needle-free” administration, especially for patients with a true needle 
phobia. In clinical trials, patients were more satisfied with inhaled insulin than with 
subcutaneous insulin31,32. Although Exubera was discontinued, other manufacturers of inhaled 
insulin are still in clinical trials24.  
For small molecules, pulmonary delivery can provide very high bioavailability and more 
rapid onset of drug action compared to the oral route. This is suitable for patients who need a 
sudden response because some drugs, particularly hydrophobic molecules, can be absorbed 
within seconds after inhalation28. Inhaled ergotamine tartrate has been studied for treatment of 
migraine for many years33. The drug itself had been used for the treatment of migraine since the 
early twentieth century34. Presently, inhaled dihydroergotamine mesylate (DHE) is being 
developed. The product, called Levadex, is waiting for FDA approval. Researchers mentioned 
that inhaled DHE should be suitable for patients who were not responding well to oral triptans 
(serotonin receptor agonists) or patients who needed a long-acting medication25. Intrapulmonary 
delivery is also being developed for seizure protection. Inhaled propofol hemisuccinate (PHS), a 
prodrug of propofol, has been administered in the form of a nebulized solution. Inhaled PHS was 
suggested to provide rapid onset for seizure protection and abort seizure clusters without causing 
prolonged sedation27. 
1.3.3 Drug Absorption, Metabolism and Clearance from the Lung 
Drug absorption is important for both locally-acting and systemically-acting drugs. Drug 
absorption may determine the residence time of the drug in the lungs, as well as the onset of 
systemic effects. Drug absorption also affects the therapeutic profile for systemic drugs. The 
absorption of pulmonary drugs depends on the drug type and site of drug deposition. Small 
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hydrophobic molecules, for example, are absorbed within seconds throughout the lungs by 
passive diffusion whereas small hydrophilic molecules are absorbed by specific transporters or 
via the tight junctions14.  
After deposition in the tracheobronchial airways or alveolar regions, the inhaled drugs 
encounter mucociliary escalator (mucus and ciliated cells) or lung surfactant, respectively6. For 
macromolecules such as peptides or proteins, mucus is a barrier to molecule access to the 
epithelium. Similarly, lung surfactant in alveolar regions may also cause a barrier for absorption 
by inducing aggregation of large molecules, resulting in engulfment and digestion by airspace 
macrophages14. However, lung surfactant was found to enhance the solubility of small molecules 
such as glucocorticosteroids35 and cationic compounds (due to the negatively charged 
phosphatidylglycerols36).  
After passing mucus or surfactant layers, drugs have to diffuse through the 0.01-10 µm 
thick lining fluid to get to epithelium that vary from monolayer columnar cells (60 µm) in the 
bronchi to monolayer squamous cells in the alveoli (0.2 µm). If absorbed into the bloodstream, 
the drugs pass through the basement membrane and the vascular endothelium37,38.  
The metabolism of several inhaled compounds occurs in lung tissue. This tissue consists 
of several cell types with different expression levels of metabolizing enzymes. CYP3A5 (the 
cytochrome P450 (CYP) families) are important detoxification enzymes in the lung tissue39. 
These cytochrome families have high expression levels in hepatocytes and enterocytes, but low 
expression in the lungs. The low metabolic activity combined with rapid absorption can result in 
high bioavailability for many small molecules; however, the formation of local metabolites 
should not be ignored since local metabolites may have therapeutic or toxic effects. In contrast, 
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local metabolism in the lungs can also have advantages for some drugs such as prodrugs and 
budesonide. Metabolic enzymes can activate prodrugs. For budesonide, the conjugation between 
budesonide and fatty acids in the lungs has been reported to lower the elimination rate, resulting 
in longer retention time and duration of effect in the lungs40,41.  
Inhaled particles can be eliminated by cough, mucociliary clearance, or alveolar 
macrophages, depending on the size of particles and the site of deposition. According to one 
publication, insoluble particles larger than 6 µm in geometric diameter are normally eliminated 
after deposition in the airways by mucociliary clearance42 whereas smaller particles can penetrate 
the mucus and enter the bronchial epithelium. In patients for whom mucociliary clearance 
decreases, coughing is more important for removal of particulates from the airways. For 
example, patients with COPD showed around 60% of particles deposited in central airways were 
eliminated by coughing compared to 8% in healthy people. The total clearance was similar in 
both groups43. Finally, slowly dissolving particles in the size range of 1.5-3 µm deposited in the 
alveolar region were found to be phagocytosed by alveolar macrophages44. 
1.4 Particle behavior in the human respiratory tract and deposition 
In general, particles are under the influence of mechanical and electrical forces but only 
charged particles are affected by electrical forces. Since pharmaceutical particles do not usually 
maintain charge, the transport of the particles in the human lungs is primarily governed by 
mechanical forces. Mechanical forces on inhaled particles cause the trajectories of inhaled 
particles to differ from airstream lines. When inhaled particles are carried with inspired air 
through the respiratory tract, the particles are displaced off airstream lines and deposited on the 
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surfaces of the respiratory tract. Drugs are deposited in the respiratory tract by three main 
mechanisms: inertial impaction, gravitational sedimentation and Brownian diffusion45.  
Inertial impaction is a velocity-dependent transport phenomenon. It occurs mainly in the 
oropharynx and large conducting airways in which the airflow velocity is maximized. When 
particles with a mass median aerodynamic diameter (MMAD) of more than 5 µm pass through 
these regions, the particles are transported toward surfaces of the respiratory tract by inertial 
impaction46. This mechanism increases with particle velocity, diameter and density. On the other 
hand, gravitational sedimentation and Brownian diffusion are time-dependent transport 
phenomena. Brownian diffusion mainly occurs in small airways where the residence time of the 
air is maximized (i.e. during breath hold). Ultrafine particles (particles smaller than 0.1 µm in 
diameter) are, in theory, deposited solely due to diffusion. This random displacement increases 
with decreasing particle diameter and is independent of the particle density. Density is more 
important for particles transported by sedimentation. Gravitational sedimentation increases with 
the size and the density of the particles45.  
The size, shape and density are important aspects of inhaled particles since they can 
affect transport properties, as well as the deposition of particles in the lungs. For example, a 
small heavy sphere can have transport properties identical to a large light sphere, resulting in the 
same deposition. Since the velocity of particles is determined by their size, shape, and density, 
particles with the same aerodynamic behavior may exhibit the same transport properties. Thus, 
the particle size is normally defined by the aerodynamic diameter (da). By considering a 
spherical particle settling under gravity through air, the aerodynamic diameter of the particle is 
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the diameter of a spherical particle with density of 1 g/cm3 that has the same settling velocity. 
The aerodynamic diameter can be calculated using the following equation45,47: 
                   (Eq.1.1) 
where ρ is the mass density of the particle, ρ0 is the unit density (1 g/cm3) and dg is the geometric 
diameter.  
The deposition of particles in the lungs can be divided into four regions: extrathoracic, 
upper bronchial, lower bronchial, and alveolar48. Particles larger than 5 µm tend to deposit in the 
mouth and upper airways whereas smaller particles (da = 1 - 5 µm) deposit deeper in the lungs. 
For deposition in the alveolar region, particles in the size range of 1 to 3 µm are desired. 
Although particles less than 100 nm have been shown to deposit in the alveolar region, most very 
small particles (da < 1 µm) are exhaled. One study showed that particles smaller than 1 µm can 
be exhaled up to 80% without deposition49. To optimize deposition in the lungs, particles should 
be small enough to avoid deposition in the mouth, throat and upper airways, but they should not 
be too small, to avoid exhalation6. 
1.5 Inhalers 
Inhalation devices can be divided into three major categories: nebulizers, meter dose 
inhalers (MDIs), and dry powder inhalers (DPIs). The first nebulizer, called a glass nebulizer, 
was introduced in the late nineteenth century. The refinement of the glass nebulizer led to the 
hand-bulb nebulizer in 1938 and then to the first MDI in 1956. DPIs were introduced in 1967, 
concurrent with the environmental concerns of chlorofluorocarbon (CFC) propellants used in 
MDIs. DPIs addressed inhalation coordination difficulties associated with the MDIs. DPIs also 
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faced problems, however, such as individual variation due to the inspiration ability of patients. 
Nebulizers, MDIs, and DPIs have been continuously refined leading to modern inhalation 
devices.  The details of the evolution of early pulmonary delivery devices have been published51. 
Nebulizers generate drug aerosols through the nebulization of suspensions or liquid 
droplets, typically water with excipients or co-solvents. Currently nebulizers can be categorized 
into three main types: compressor (air jet), ultrasonic, and vibrating mesh. Compressor 
nebulizers are air-driven devices. The liquid stream is broken into aerosol droplets by the 
compressed air pressure. Droplets in the size range of 1-5 µm can reach the lower airways while 
droplets larger than 5 µm are more likely to be filtered out by impaction within the device or 
recirculated in the nebulizer reservoir. This recycling of large droplets can increase drug 
concentration in solution52. Moreover, the drug lost in the nebulizer and the mask or mouthpiece 
can lower efficiency or cause inter-patient variability.  
 Ultrasonic nebulizers have a piezoelectric crystal for generating high frequency 
vibrations. The vibrations are transmitted through liquid medicine to generate fine aerosols 
delivered to patients. The aerosol from these nebulizers may be larger than the aerosols from 
compressor nebulizers. Ultrasonic nebulizers have limited use with suspensions or formulations 
with high viscosity. Ultrasonic nebulizers, however, have advantages of silent operation, less 
time of nebulization and higher dosing efficiency.  
Vibrating mesh nebulizers have recently been developed to overcome many 
disadvantages of conventional compressor and ultrasonic nebulizers. Vibrating mesh technology 
uses the piezoelectric crystal to vibrate a mesh plate in contact with the drug. Aerosols are 
generated as a fine mist when liquid medication passes through the holes of the vibrating metal 
grid. The pore size of the mesh and output rate can be adjusted to optimize performance for 
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different drugs. These devices also have quiet operation, high nebulization rates, and have been 
optimized for small volume formulations53. Consequently, the treatment time is also decreased. 
Pressurized metered-dose inhalers (pMDIs) are a convenient and accepted mode of for 
delivering drug medications to patients with asthma and COPD worldwide. Approximately 500 
million pMDIs are produced each year since they are cheaper and more portable than other 
devices. pMDIs can be used to deliver both solutions and suspension formulations by actuating 
the device to release a metered dose of propellant-drug aerosols through a valve system54.  
The key components of pMDI consist of propellant, formulation, metering valve and 
actuator. The particle size distribution of the aerosols depends on the physicochemical properties 
of the formulation and the device design55. Drugs are dissolved or suspended in a liquid 
propellant and surfactants such as oleic acid may be added to disperse drug particles in 
suspension and lubricate the valve mechanism in the CFC-containing pMDIs. The high 
concentration of non-volatile surfactants in some formulations may increase the droplet size of 
the aerosols because they slow down evaporation of volatile propellants. Propellants used in the 
pMDIs have been changed from chlorofluorocarbons (CFCs) to hydrofluoroalkanes (HFAs) due 
to environmental concerns. Some surfactants commonly used in CFC pMDIs are insoluble in 
HFAs. In this case, ethanol can be used as a low-volatility co-solvent in HFA formulations to 
solubilize the surfactants or solubilize the drug itself. Metering valves function to deliver a 
reproducible amount of drug formulations. Spray actuators combined with the stem of the 
metering valve function to spray formulations via the actuator nozzle. The compatibility of the 
formulation with the metering valve and the design of the actuator are important since variable 
concentration of suspension at the inlet can cause a variation in drug dosing. Aerosol particle size 
also depends on the nozzle diameter. Moreover, the pMDIs require coordination between 
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actuation and inhalation to optimize drug deposition in the lungs. This requirement can cause 
variability in pMDIs due to patient misuse56. 
Dry powder inhalers (DPIs) are breath-actuated devices that have emerged as the most 
popular inhalation device. There are over 20 DPIs on the market and more than 25 in 
development58. DPIs can be categorized into three types: single-unit dose devices, multi-dose 
reservoir devices, and multi-unit dose devices. In single-unit dose devices such as the 
Handihaler™, each dose is loaded into a capsule, which is inserted into the device before use. 
After use, the capsule has to be removed before a new one can be placed in the device. Because 
of the capsule replacement for each dose, Single-unit dose devices are inconvenient for patients 
compared to multi-dose DPIs. Multi-dose DPIs can be multi-dose reservoir devices, which 
contain drug powders that are released with each actuation, or multi-unit dose devices which 
contain multiple capsules or blisters. Multi-unit dose devices can provide more reproducible 
doses compared to the multi-dose reservoir devices58.  
 In general, DPIs are passive devices in which the delivery efficiency depends on 
inspiration efforts of patients. The DPIs were designed to induce sufficient turbulence airflow to 
deagglomerate drug particles. DPI formulations can contain the drug mixed with excipients or 
the drug itself. Lung deposition from these devices has been reported to vary from 12 to 40%58. 
Since the drug delivery efficiency of DPIs depends on turbulent airflow to aerosolize drug 
formulations, the device design, drug formulation, and inspiration flow pattern are all important. 
1.6 Relationship of drug formulations and DPIs 
The size of wet aerosols is affected by the device and formulation properties such as 
surface tension. Similarly, DPIs disperse powders and this process is significantly impacted by 
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the formulation. Nebulizers and pMDIs use liquid formulation to generate wet aerosols whereas 
DPIs generate dry powder aerosols via deagglomerating of drug formulations. Although the 
devices produce different kinds of aerosols, effective aerosols should have aerodynamic 
diameters of 1-5 µm to deposit in the lungs or 1-3 µm to deposit in the alveolar region. 
Particles in dry powder formulations can be engineered in many ways such as deceasing 
particle density, lowering surface energy, and changing the morphology of the particles. For 
example, porous particles are designed to decrease aerodynamic diameters of the particles. 
Because of their low density and large geometric diameter, these particles can have aerodynamic 
diameters similar to smaller and denser particles but with less surface energy. Engineered 
particles can have rough surfaces to increase the air drag force. For instance, non-porous 
corrugated particles showed enhance aerosol performance over smooth spherical particles. The 
inhaler device and airflow also showed diminished influence on the dispersion behavior of these 
particles compared to smooth particles59. These particles have less contact area between the 
particles, resulting in reduced cohesion of the drug powder. The aerosol performance can also be 
enhanced by using fine carriers such as lactose or other excipients (e.g. a lubricant). Fine lactose 
carriers were found to enhance the powder flow and also increase the powder bulk for capsule 
filling60. 
The design of the device is also important to control the size range of particles emitted 
from the DPI61. The device design contributes to deagglomeration and dispersion of drug 
powders. Deagglomeration of powders tends to increase as shear force increases. Although the 
shear force may be increased by increasing flow rate, the impaction of drug powders may be 
increased at high flow velocity, as well, resulting in loss of drug powders in the mouth, throat 
and upper airways.  
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The resistance of devices affects the turbulence of air through the devices. Normally, 
high resistance DPIs will generate higher turbulence, leading to higher fine particle fraction 
(FPF) of drug formulations62. DPIs with similar resistance, however, may also have different 
dispersion efficiency because of the different turbulence patterns in the DPI. The turbulence 
pattern of the device is caused by the internal geometry of the device such as the dimensions and 
shape of the air channels. For example, a study showed an important role of grid structure on 
inhaler performance. They suggested that the inhaler grid directly affected the amount of powder 
retention within the device by affecting the frequency of contact between the particle and the 
mouthpiece63. The comparison of two DPIs, which have similarly low resistances of 0.03 – 0.04 
cmH2O1/2/L/min, showed the FPF using the Dinkihaler® were higher than with the Rotahaler® 
due to the higher dispersion efficiency of Dinkihaler®61. In addition, different formulations can 
show different performance even when employing the same device. Thus, particle engineering 
normally occurs concurrently with the development of devices. Most of the DPIs on the market 
have been designed for use with particular drug formulations. 
1.7 Drug delivery in mechanical ventilation 
In the past, aerosol delivery in patients on mechanical ventilation was difficult due to the 
very poor efficiency of drug delivery through a ventilator circuit and an endotracheal tube. 
Moreover, lack of understanding and the dated technology of ventilators contributed to 
unsuccessful aerosol delivery64. Although various kinds of inhalers have been developed for 
delivering drug aerosols into ambulatory patients, only nebulizers and pMDIs have been 
routinely used for clinical therapy during mechanical ventilation. Drugs lost in the ventilator 
circuit and the endotracheal tube are still major barriers to the success of aerosol drug delivery 
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during mechanical ventilation65. For example, in vitro studies of a bronchodilator drug delivered 
by jet nebulizers showed only a very low quantity of inhaled drugs deposited on the filter at the 
end of an endotracheal tube66. Drug dosing is also highly variable67. Inhalation therapy is still 
common during mechanical ventilation, meanwhile new inhalers and connections are being 
developed68,69. Furthermore, factors that affect the efficiency of drug delivery in these patients 
have been investigated. 
1.7.1 Ventilator circuit-related factors influencing aerosol delivery during mechanical 
ventilation 
   In general, patients who have a severe breathing problem have to be on mechanical 
ventilation. A ventilator provides mechanical assistance or replaces spontaneous breathing for 
patients. It controls the respiratory system of patients on mechanical ventilation using different 
parameters, which can play a role on aerosol drug delivery to these patients. Thus, to improve 
drug delivery efficiency to ventilated patients, some parameters such as inspiration patterns, 
inspiration volume, volumetric flow rate, humidity and tubing are normally investigated.  
1.7.1.1 Inspiration patterns 
 A mechanical ventilator can control phases of breathing in either mandatory or 
spontaneous modes that can be categorized into three types: continuous mandatory ventilation 
(CMV), intermittent mandatory ventilation (IMV), and spontaneous mode. The CMV mode is a 
full ventilation support mode that is selected for patients with respiratory failure, especially those 
who have a problem of inadequate alveolar ventilation. Mechanical ventilation can be applied in 
patients by using assisted or controlled modes of support. The assisted mode offers many 
advantages over controlled mode such as reducing the need for sedation and paralysis, 
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decreasing the risk of barotrauma, and preventing muscle atrophy70. During assisted ventilation, 
a ventilator pump influences patient breathing. The control of breathing depends on both 
ventilator settings and the patient’s ventilatory demand and respiratory system mechanics. 
Therefore, the interplay between the ventilator and patient’s control over their breathing may 
lead to patient-ventilator asynchrony71. Patient-ventilator asynchrony occurs when there is a 
mismatch between the inspiration of the patient and mechanically assisted breath, which prevents 
the ventilator from aiding breathing and may cause injury to the patients72.  
A primary goal of mechanical ventilation is not only to improve gas exchange but also to 
reduce the work of breathing (WOB). Improper ventilator settings can increase WOB which can 
lead to muscle fatigue and hypercapnia73. Normally, inspiration patterns on a ventilator can be 
categorized into three kinds of waveforms; sine, ramp (decelerating), and square waveforms. A 
sine waveform provides a continuous increase and decrease of flow rate in the form of a sine 
wave. A ramp waveform generates the highest inspiration flow rate at the beginning of the cycle, 
and then the flow rate gradually decreases along the cycle. A square waveform provides a 
constant flow rate throughout an inspiration cycle74. A suitable waveform depends on the mode 
of the ventilator setting. A square waveform, for example, is traditionally applied for volume-
limited breaths during ACV. The decelerating ramp waveform is also often used in volume-
limited modes. The ramp waveform was recommended for patients with COPD requiring 
intermittent positive-pressure ventilation (IPPV)75. The ramp waveform showed the lowest WOB 
compared to sine and square waveforms. It also improved lung mechanics and optimized gas 
exchange. In patients with normal respiratory mechanics, inspiration patterns have no major 
effect on gas exchange and WOB. Nevertheless, in patients with a more severe lung injury, the 
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ramp waveform may be more effective since it may allow more time for gas distribution in the 
alveoli70.  
In terms of drug delivery, a study showed that inspiration pattern caused statistically 
significant differences in nebulizer performance76. The square waveform produced higher output 
efficiencies and a constant output particle size over a breathing cycle. A simulation of different 
waveforms, however, suggested that the square waveform produced slight over predictions of 
output compared to real nebulizer patterns. The sine waveform showed the same results as 
nebulizer patterns in both the bench tests and in simulations. This suggested that the sine 
waveform was more suitable for testing drug delivery during nebulization. The sine waveform is 
commonly utilized in respiratory therapy under mechanical ventilation. During inspiration at 
rest, the inspiration breathing is theoretically a sine function over time73. 
1.7.1.2 Inspiration volume 
 Patients with respiratory diseases such as COPD normally have lower inspiratory 
capacity compared to healthy people77. A study reported that setting the tidal volume at greater 
than 500 mL in an adult model improved aerosol drug delivery78. Although the large tidal 
volume may increase aerosol deposition efficiency, caution should be used since it also can 
cause volutrauma if it is greater than 8-10 mL/kg79. 
1.7.1.3 Volumetric flow rate 
Volumetric flow rate dictates flow in the system. High flow rate can increase turbulence 
and also the inertial impaction of aerosols. Some studies suggested that a lower inspiration flow 
rate (e.g. 40 versus 80 L/min) improved aerosol delivery in both non-ventilated patients and 
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ventilated patients65,80. Aerosol delivery had a direct correlation with duty cycle (inspiratory time 
(TI)/duration of total breathing cycle (TTOT). Investigators found that increasing the duty cycle 
(TI)/ (TTOT) improved lower-respiratory-tract aerosol delivery67. The longer inspiratory time 
allows a larger proportion of the nebulizer-generated aerosol to be inhaled with each breath. 
With the jet nebulizer, more albuterol was delivered with longer inspiratory times81. Another 
study also found greater albuterol delivery to the bronchi with a TI/Ttot of 0.50 than of 0.25 when 
delivered via MDIs. The study reported a greater effect of volumetric flow rate compared to 
TI/Ttot on aerosol delivery. The delivery of albuterol was twofold greater when applied at 40 
L/min compared to at 80 L/min65. Moreover, if the expiratory time is excessively shortened, 
dynamic hyperinflation may complicate the use of longer inspiratory times. For routine clinical 
use, a slower inspiratory flow rate was preferred to excessively long inspiratory times to 
maximize aerosol delivery. The investigators suggested that aerosol delivery in ventilated 
patients should ‘go slow with the flow’82.  
Volumetric flow rate is also important for aerosol delivery when using DPIs. Most all 
DPIs on the markets are passive inhalers. DPI performance is typically flow dependent. The 
dispersion of drug powders depends on the inspiration effort of the patient and the resistance 
within the inhaler. As mentioned previously, a higher flow rate can increase turbulence. 
Turbulence has an important effect on powder dispersion, potentially resulting in an increased 
dispersion of powders. Since turbulence and powder impaction may increase when applied at a 
higher flow rate. The effect of the flow rate on powder performance is, thus, an important 
parameter when delivering drug aerosol to ventilated patients. 
 




Ventilator circuits are often humidified and heated. Approximately 40-50% of drugs can 
be lost when heated/humidified ventilator circuits are used83,84. Investigators suggested that drugs 
were lost in the humidified ventilator circuit because of increasing particle impaction in the 
ventilator tubing. Fink et al. found greater albuterol deposition in the ventilator circuit and the 
endotracheal tube caused lower drug delivery to a lung model when the aerosol was delivered via 
pMDI65. Miller et al. also reported an increase of particle size due to droplet growth when 
albuterol was delivered via a nebulizer in a humidified circuit85. The loss of drug aerosol can be 
reduced by turning off or bypassing a humidifier during aerosol administration. Bypassing the 
humidifier for a long time, however, can harm the airway mucosa, which could be exacerbated 
by in the case of some nebulizers that require up to 35 minutes to complete aerosolization83. 
Although the pMDI required a short interval to administer aerosols, disconnecting the ventilator 
circuit to bypass the humidifier can increase the risk of infection or ventilator-associated 
pneumonia in both nebulizer and pMDI use. Therefore, humidification may be maintained during 
pMDI or nebulizer delivery of bronchodilators84. For a very expensive drug such as an 
“antibiotic”, a dry circuit could be employed, but drug administration was advised to be achieved 
within 10 minutes or less86.  
Relative humidity is also known to affect dry powder aerosols. A study showed lower 
drug delivery efficiency in both dry and humid environments depending on the physicochemical 
nature (i.e. hygroscopicity) of the drug87. For example, drug delivery efficiency can be decreased 
because of capillary force between the particles in a humid environment88,89 or due to static 
charges between the particles in a dry environment90. Previous works from our group showed 
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decreasing drug delivery efficiency when powders were applied through an endotracheal tube at 
lower relative humidity (40% RH compared to 50% RH)91. Conversely, another study showed 
lower drug delivery efficiency during mechanical ventilation when powder aerosol was applied 
at 82% RH compared to at 55% RH92. 
1.7.1.5 Endotracheal tube and device placement in the circuit. 
 Aerosol medication in mechanically ventilated patients is routinely administered through 
an endotracheal tube. The endotracheal tube is passed through the mouth or nose into the trachea. 
The narrow diameter of endotracheal tubes, compared to the normal upper airway, create higher 
air flow resistance in ventilated patients compared to non-ventilated patients. The resistance of 
the endotracheal tube depends on inspiratory airflow. When a high inspiratory airflow is 
employed during mechanical ventilation, high shear and turbulence may be generated. Both 
airway resistance and turbulence influence aerosol deposition in the lung and along the tube. 
Since the endotracheal tube is the narrowest part of the ventilator circuit, the highest resistance to 
air flow is created in this area. The endotracheal tube may substantially reduce aerosol delivery 
in ventilated patients. A study showed that pulmonary deposition decreased 10-14% in these 
patients compared to ambulatory patients93. 
Aerosol delivery through endotracheal tubes is influenced by many factors such as 
endotracheal tube size, endotracheal tube material/design, the type of aerosol generator used, and 
ventilator settings. An in vitro study by Crogen and Bishop reported a decrease of aerosol 
delivery to the filter with reduction of the inner diameter of the endotracheal tube94. Some 
investigators mentioned, however, that these reports might have overestimated the aerosol-
delivery impediment created by the endotracheal tube due to the closer placement of the aerosol 
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generator to the tube84. The placement of the aerosol generator also influences the aerosol 
deposition within the tube. A study showed that the deposition within the tube was decreased and 
the deposition in the lungs was increased when the aerosol generator was placed farther away 
from the endotracheal tube84. Similar to another study, placing nebulizers closer to the ventilator 
instead of closer to the patient decreased aerosol impaction in the tube. In addition, using a 
spacer with a pMDI, a study showed reduction of aerosol loss within the tube when placing the 
spacer at a distance of at least 15 cm from the endotracheal tube93. Although investigators 
mentioned that the type of aerosol generator and the ventilator settings had a greater effect than 
the tube size, the appropriate size should be selected to minimize aerosol loss within the tube. 
“Priming” the tube with a few doses before use may also reduce aerosol deposition within the 
tube by blocking electrostatic charge on the inner walls of the tube93. 
The endotracheal tube is normally coated with a bacterial biofilm within hours of intubation95. A 
study showed biofilm developed within 6 hours of ventilation. The microorganisms may be 
transported into the pulmonary tree and cause infection and ventilator-associated pneumonia 
(VAP)95,96. The presence of biofilms in narrow endotracheal tubes can potentially cause tube 
obstruction97,98. This type of obstruction can appear during the first 24 h of mechanical 
ventilation98.  The study showed more than 10% obstructions occurred in around 60% of patients 
and 22% of them showed that the tube inner-diameter reached critical values98. Moreover, mucus 
and secretion within the tube may alter gas flow, create turbulence, increase work of breathing 
and cause the release of fluid droplets99,100. A traditional way to remove mucus lodged within the 
endotracheal tube is via a suction catheter, which is inserted into the endotracheal tube. Although 
this method may not remove all secretions, the process of suction can be repeated frequently100. 
A study in sheep showed that the sterile suctioning of the endotracheal tube was performed every 
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6 hours or as needed101. Furthermore, a new technology such as the Muscus Shaver was 
developed in order to improve the efficiency of removing secretions from the endotracheal 
tube96,100. 
1.7.2 The differences in direct-to-mouth and ventilator aerosol delivery  
 Many aerosolized drugs are delivered to conducting airways to minimize systemic 
exposure and to achieve high local concentration. To treat pulmonary diseases such as asthma or 
COPD, aerosolized drugs are delivered to patients by direct-to-mouth oral inhalation. The 
portion that deposits on the tongue or the back of the pharynx may be swallowed and absorbed in 
the gastrointestinal (GI) tract. Drug could then distribute systemically or be inactivated by first-
pass metabolism in the liver. This portion of the aerosol drug can cause adverse side effects or 
can waste valuable medication.  
In contrast to outpatients who receive inhaled drugs direct-to-mouth, patients on 
mechanical ventilation are delivered inhaled drugs through an endotracheal tube. The 
endotracheal tube is inserted into the mouth until just above the first bifurcation. Therefore, 
systemic adverse effects caused following deposition in the mouth and swallowing can be 
bypassed. Nevertheless, a large amount of drug loss in the endotracheal tube can impede drug 
delivery in ventilated patients.  
1.7.2.1 The effect of airway geometry  
In general, deposition patterns in human airways are controlled by three major factors: 
the aerodynamic particle size distribution, the inhalation flow rate, and airway geometry. The 
first two factors are related to the aerosol generation system and formulation whereas the airway 
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geometry is strictly a patient characteristic. The geometric complexity affects flow and particle 
transport dynamics inside the airways102. Low velocity was reported for the oral cavity, whereas 
a higher velocity was found in the pharynx/larynx region, and the velocity increased rapidly after 
the glottis103.  
For non-ventilated patient, many studies have tried to understand and predict the behavior 
of particles and airflows along the airway104,105 by modeling the geometric surface of the 
extrathoracic oral airways extending from the mouth through the larynx 103. Simulated velocity 
profiles in the pulmonary airway include an oral-tracheobronchial airway model and a 
bifurcation airway model during inhalation106. Numerical predictions have to be developed 
further to improve geometric and physical realism107.   
In ventilated patients, although using an endotracheal tube can bypass the deposition and 
variation of airflow in the upper airways, the airway geometry is also important for drug 
delivery. The airway geometry has an influence on turbulent fluctuations along the airways. 
Turbulent airflow may enhance the deposition of nanoparticles in the upper airway, especially at 
a high flow rate. Lower deposition of vapors was observed at a higher flow rate because a longer 
residence time favors deposition of small particles102.  
1.7.2.2 The effect of device geometry  
The device geometry influences aerosol performance in both non-ventilated patients who 
received inhaled drugs through the mouth and ventilated patients who received the drug through 
an endotracheal tube. Inhalation devices have been modified to increase drug delivery. For 
patients who receive inhaled drugs direct-to-mouth, inhaled aerosols can be delivered via 
different kinds of inhalers. Both geometry of the oral airways and geometry of the device are 
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important to deliver the drug aerosol to the lung, and avoid deposition in the device or in the 
extrathoracic cavity.  
pMDIs with a spacer and a smaller exit diameter nozzle, for example, reduce droplet size 
and spray inhalation speed, resulting in higher deposition efficiency. Moreover, drug delivery via 
the same system with or without a spacer was also simulated108. Besides nebulizers and pMDIs, 
DPIs is an alternative inhaler for widely using with non-ventilated patients. Drug delivery from 
DPIs depend on a combination of device and formulation properties109. Aerosolization 
performance of different DPIs was studied to identify and understand the key performance 
attributes of DPI devices at different flow rates63,110. Devices have a specific resistance that can 
affect the fluidization and dispersion of drug powders111. In order to compare performance, these 
behaviors should be investigated in both a test device and a reference device110. Generally, the 
dispersion performance from DPIs depends on both patients’ inspiration efforts and the 
resistance of the device. For instance, patients with different ages such as preschool children and 
elderly people can have dramatically different abilities to generate inspiratory flows. In 
preschool children, some studies found that children had to be older than 5 years to maintain 
dose consistency112 . At the same time, the ability of children112,113 and elderly patients114,115 to 
provide sufficient inspiration flow depended on the resistance of DPIs. Therefore, the fluid 
dynamics of DPIs were investigated at different flow rates. The studies suggested that if details 
of the device flowfield are known, the dispersion performance of DPIs could be predicted116.  
The understanding of device geometry can be applied for ventilated patient also. The 
important of device that influenced aerosol drug delivery in this kind of patients was discussed in 
the following section. Although DPIs have not been used with ventilated patient, the 
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understanding of DPI geometry should benefit the development of DPIs for ventilated patient in 
advance. 
1.7.3 Device-related factors influencing aerosol delivery during mechanical ventilation 
Drug medication such as bronchodilators, corticosteroids, and antibiotics are delivered to 
ventilated patients by using either nebulizers or pMDIs. Nebulizers have been commonly used 
for drug delivery with these patients for quite some time. Over the past 25 years, however, 
pMDIs have been accepted for administering inhaled aerosols to ventilated patients because of 
effective cost, convenience, reliability and the safety of these devices117. Since the devices are 
important determinants of the efficiency of drug delivery, device design and performance factors 
should be considered.  
Nebulizer and pMDI devices have different mechanisms to generate aerosol. The factors 
that affected aerosol delivery of the nebulizers included nebulizer type, residual volume, 
nebulizer mode, position of the nebulizer and gas flow79. Three different types of nebulizers have 
been used for aerosol drug delivery during mechanical ventilation but jet nebulizers are the most 
commonly used in hospitals because of the ease of use and because they are typically cheaper 
than vibrating mesh and ultrasonic types. Most jet nebulizers, however, are less effective than 
ultrasonic and vibrating mesh nebulizers. A study showed lower efficiency during mechanical 
ventilation of jet nebulizers compared to ultrasonic nebulizers although the aerosol deposition in 
the lungs was poor for both (5.3±1.4 % for ultrasonic nebulizers and 2.3±0.9 % for jet 
nebulizers)118. Different brands and different batches of the same brands can also lead to 
variability in aerosol deposition66,119-121. A study showed broad variability of nebulization time 
and total amount of drug delivered to the lungs of ventilated patients among different 
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commercial nebulizers121. The high cost, the bulkiness, and the relative inefficiency of 
nebulizing drug suspensions limits the use of ultrasonic nebulizers in both non-ventilated patients 
and ventilated patients86. 
Ultrasonic nebulizers and vibrating mesh nebulizers can provide a higher nebulization 
rate in a shorter period of time compared to jet nebulizers122. Since jet nebulizers do not function 
well with small fill volumes, the medication may have to be diluted to increase the volume, thus 
increasing the treatment time. Moreover, at the end of nebulization, jet nebulizers retain high 
residual volumes in the reservoir. The residual volume of jet nebulizers is 0.8-1.4 mL whereas 
the residual volume ranges from 0.5 - 1.0 mL in ultrasonic nebulizers and 0.1- 0.5 mL in 
vibrating mesh nebulizers123. Because vibrating mesh nebulizers have the lowest residual 
volume, they usually offer higher efficiency than the other two nebulizers. Moreover, vibrating 
mesh nebulizers can decrease the risk of contamination entering the mediation reservoir because 
the medication reservoir is separated from the ventilator circuit by the mesh. On the other hand, 
jet nebulizers are designed for varied levels of compressed air flow and pressure. The 
compressor or gas source should be matched with the jet nebulizer design otherwise the particle 
size of drug aerosols may be increased124. The treatment time in jet nebulizers is also affected by 
gas flow rate, which is not pertinent for electrically powered nebulizers such as ultrasonic and 
vibrating mesh nebulizers. 
Another factor that affects aerosol delivery in nebulizers is the mode of nebulization. 
Some studies found that intermittent nebulization was more efficient than continuous 
nebulization since aerosol loss during exhalation was minimized66. The position of the nebulizer 
may also play a role in aerosol delivery efficiency. A study suggested that the nebulizer should 
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be placed prior to the humidifier to increase drug delivery, especially with the vibrating-mesh 
nebulizer, although drug delivery with the vibrating-mesh nebulizer was 2-4 fold greater than 
with the jet nebulizer at all positions69.  
 Like nebulizers, the position of a pMDI in ventilator circuit also affected the efficiency of 
aerosol delivery. Researchers used in vitro models of adult mechanical ventilation to compare the 
efficiency of aerosol generators at different positions in the ventilator circuit under both dry and 
humidified conditions. They found that the ultrasonic nebulizer, the vibrating mesh nebulizer, 
and pMDIs with spacer placed in the inspiratory limb 6 inches from the Y adapter yielded the 
highest deposition125. Other factors that affect the efficiency of pMDIs are actuation and priming 
and shaking the canister. Actuation of the pMDIs should be synchronized with the precise onset 
of inspiration to maximize aerosol drug delivery. A reduction of inhaled mass by 35% was 
reported when actuation was not synchronized with inspiration83. Also, a study showed at least 
40% higher dose when pMDI was actuated at the onset of inspiration compared to actuation 
during expiration126. pMDIs need to be primed and shaken well before the first actuation of each 
dose administered because the drugs in the pMDI formulation tend to separate from the 
propellants when standing, resulting in decreasing total and respirable dose by as much as 25 and 
35%, respectively127. 
 Nevertheless, the variability of drugs delivered to the lungs due to the low efficiency of 
liquid formulations beckons the development of dry aerosol powder technology for ventilated 
patients. Although DPIs are not available for ventilated patients, there are some studies of DPIs 
modified for use during mechanical ventilation. For example, the Turbuhaler® was modified by 
removing the outer covering of the Turbuhaler® and putting it in a closed chamber that connected 
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to the ventilator circuit128. The researchers suggested that dry powder drug delivery was worthy 
of further development, especially in the intensive care setting, although some drug was lost in 
an endotracheal tube. The percent of drug lost should be reduced when a dry endotracheal tube 
and non-humidified system are applied79. Furthermore, an engineered dry powder formulation 
should increase the drug delivery efficiency during mechanical ventilation. 
1.7.4 Dry powders with DPIs in mechanical ventilation 
 As mentioned previously, only nebulizers and pMDIs are currently used in routine 
clinical practice for delivering drug aerosols to ventilated patients. Investigators have studied the 
factors that influence delivery of aerosols and explored factors such as changing the position of 
the aerosol generator or developing appropriate inhalers. Still, liquid formulations suffer from 
variability and poor efficiency of aerosol delivery, especially in humid environments. Moreover, 
aerosols generated from both wet nebulizers and pMDIs can induce bronchoconstriction in 
ventilated patients with obstructive airway disease128.  
Delivery of inhaled drugs in the form of dry powders to ventilated patients is now an 
attractive alternative. It can eliminate the problem of ‘raining out’ or condensation of droplets in 
the tubing. Advances in particle engineering also compel efforts to explore drug powder 
formulations in ventilated patients. For example, drug particles have been engineered by 
applying nanotechnology to pharmaceutical formulation designs. Micron-scale dry powders of 
nanoparticles have been formulated in the form of agglomeration of nanoparticles known as 
“NanoClusters.” NanoCluster formulations can provide the combination of nano-scale particle 
and micro-scale particle. In other words, NanoClusters have higher dissolution compared to 
micronized drug particle129. At the same time, the low density of NanoClusters in the size range 
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of 1-3 um should navigate to the deeper area in the lung and be suitable for deposition in the 
lower respiratory tract47,48. 
In non-ventilated patients, dry powder is delivered via DPIs. Although DPIs have not 
been used to deliver inhaled drugs to patients on mechanical ventilation, the development of 
DPIs in use with ventilation systems is continuously growing128. DPIs pose new challenges such 

















1. Kelly MM, O'Connor TM, Leigh R, Otis J, Gwozd C, Gauvreau GM, Gauldie J, O'Byrne 
PM 2010. Effects of budesonide and formoterol on allergen-induced airway responses, 
inflammation, and airway remodeling in asthma. Journal of Allergy and Clinical Immunology  
125(2):349-356. e313. 
2. Christensson C, Thorén A, Lindberg B 2008. Safety of inhaled budesonide. Drug Safety  
31(11):965-988. 
3. Singh S, Amin AV, Loke YK 2009. Long-term use of inhaled corticosteroids and the risk 
of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Archives of internal 
medicine  169(3):219. 
4. Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL, Williams III 
RO 2006. Single dose and multiple dose studies of itraconazole nanoparticles. European journal 
of pharmaceutics and biopharmaceutics  63(2):95-102. 
5. Gandevia B 1975. Historical review of the use of parasympatholytic agents in the 
treatment of respiratory disorders. Postgraduate medical journal  51(7 SUPPL):13. 
6. Patton JS, Byron PR 2007. Inhaling medicines: delivering drugs to the body through the 
lungs. Nature Reviews Drug Discovery  6(1):67-74. 
7. Muthu DC. 1922. Pulmonary tuberculosis: its etiology and treatment, a record of twenty 
two years' observation and work in open-air sanatoria. ed.: Bailliere, Tindall & Cox. 
8. Manthous CA, Hall JB, Schmidt GA, Wood LDH 1993. Metered-dose inhaler versus 
nebulized albuterol in mechanically ventilated patients. American journal of respiratory and 
critical care medicine  148(6 Pt 1):1567-1570. 
9. Plumley CJ 2008. Nanoparticle Agglomeration via Ionic Colloidal Destabilization as a 
Novel Approach to Dry Powder Formulations for Pulmonary Drug Delivery. 
10. Hofmann W 2011. Modelling inhaled particle deposition in the human lung—A review. 
Journal of aerosol science  42(10):693-724. 
11. Bisgaard H, O'Callaghan C, Smaldone GC. 2001. Drug delivery to the lung. ed.: Informa 
Healthcare. 
12. Hoet PHM, Brüske-Hohlfeld I, Salata OV 2004. Nanoparticles–known and unknown 
health risks. Journal of Nanobiotechnology  2(1):12. 
13. West JB. 2011. Respiratory physiology: the essentials. ed.: Lippincott Williams & 
Wilkins. 
14. Patton JS 1996. Mechanisms of macromolecule absorption by the lungs. Advanced Drug 
Delivery Reviews  19(1):3-36. 
15. Labiris N, Dolovich M 2003. Pulmonary drug delivery. Part I: physiological factors 
affecting therapeutic effectiveness of aerosolized medications. British journal of clinical 
pharmacology  56(6):588-599. 
16. Rubin BK, Fink JB 2001. Aerosol therapy for children. Respiratory care clinics of North 
America  7(2):175. 
17. Tronde A, Nordén B, Marchner H, Wendel AK, Lennernäs H, Bengtsson UH 2003. 
Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure–absorption 
relationships and physicochemical profiling of inhaled drugs. Journal of pharmaceutical sciences  
92(6):1216-1233. 
	   	  
34	  
	  
18. Ruffin R, Dolovich M, Wolff R, Newhouse M 1978. The effects of preferential 
deposition of histamine in the human airway. The American review of respiratory disease  
117(3):485. 
19. Usmani OS, Biddiscombe MF, Barnes PJ 2005. Regional lung deposition and 
bronchodilator response as a function of β2-agonist particle size. American journal of respiratory 
and critical care medicine  172(12):1497-1504. 
20. Adcock IM, Gilbey T, Gelder CM, Chung KF, Barnes PJ 1996. Glucocorticoid receptor 
localization in normal and asthmatic lung. American journal of respiratory and critical care 
medicine  154(3):771-782. 
21. Aaron S, Aaron SD 2001. The use of ipratropium bromide for the management of acute 
asthma exacerbation in adults and children: a systematic review. Journal of Asthma  38(7):521-
530. 
22. Partridge M, Saunders K 1981. Site of action of ipratropium bromide and clinical and 
physiological determinants of response in patients with asthma. Thorax  36(7):530-533. 
23. Vachier I, Chiappara G, Vignola AM, Gagliardo R, Altieri E, Terouanne B, Vic P, 
Bousquet J, Godard P, Chanez P 1998. Glucocorticoid receptors in bronchial epithelial cells in 
asthma. American journal of respiratory and critical care medicine  158(3):963-970. 
24. McMahon GT, Arky RA 2007. Inhaled insulin for diabetes mellitus. New England 
Journal of Medicine  356(5):497-502. 
25. Rapoport AM 2010. New acute treatments for headache. Neurological Sciences  
31(1):129-132. 
26. Armer T, Shrewsbury S, Newman S, Pitcairn G, Ramadan N 2007. Aerosol delivery of 
ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Current Medical 
Research and Opinion®  23(12):3177-3187. 
27. Dhir A, Zolkowska D, Murphy RB, Rogawski MA 2011. Seizure protection by 
intrapulmonary delivery of propofol hemisuccinate. Journal of Pharmacology and Experimental 
Therapeutics  336(1):215-222. 
28. Patton JS, Fishburn CS, Weers JG 2004. The lungs as a portal of entry for systemic drug 
delivery. Proceedings of the American Thoracic Society  1(4):338-344. 
29. Lenzer J 2006. Inhaled insulin is approved in Europe and United States. Bmj  
332(7537):321. 
30. Becquemin MH, Chaumuzeau JP 2010. Inhaled insulin: A model for pulmonary systemic 
absorption? Revue des maladies respiratoires  27(8):e54-e65. 
31. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA 2004. Patient satisfaction and 
glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 
diabetes. Diabetes Care  27(6):1318-1323. 
32. Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA 2002. Treatment 
satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a 
subcutaneous insulin regimen. Clinical therapeutics  24(4):552-564. 
33. Crooks J, Stephen S, Brass W 1964. Clinical trial of inhaled ergotamine tartrate in 
migraine. British medical journal  1(5377):221. 
34. Rothlin E 1955. Historical development of the ergot therapy of migraine. International 
Archives of Allergy and Immunology  7(4-6):205-209. 
35. Wiedmann T, Bhatia R, Wattenberg L 2000. Drug solubilization in lung surfactant. 
Journal of controlled release  65(1):43-47. 
	   	  
35	  
	  
36. Liao X, Wiedmann TS 2003. Solubilization of cationic drugs in lung surfactant. 
Pharmaceutical research  20(11):1858-1863. 
37. Olsson B, Bondesson E, Borgström L, Edsbäcker S, Eirefelt S, Ekelund K, Gustavsson L, 
Hegelund-Myrbäck T 2011. Pulmonary Drug Metabolism, Clearance, and Absorption. 
Controlled Pulmonary Drug Delivery:21-50. 
38. Eljamal M, Nagarajan S, Patton JS 1996. In situ and in vivo methods for pulmonary 
delivery. Pharm Biotechnol  8:361-374. 
39. Anttila S, Hukkanen J, Hakkola J, Stjernvall T, Beaune P, Edwards RJ, Boobis AR, 
Pelkonen O, Raunio H 1997. Expression and localization of CYP3A4 and CYP3A5 in human 
lung. American journal of respiratory cell and molecular biology  16(3):242. 
40. Tunek A, Sjödin K, Hallström G 1997. Reversible formation of fatty acid esters of 
budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug 
metabolism and disposition  25(11):1311-1317. 
41. Den Brink V, Maassen KI, Boorsma M, Staal-­‐van den Brekel AJ, Edsbäcker S, Wouters 
EF, Thorsson L 2008. Evidence of the in vivo esterification of budesonide in human airways. 
British journal of clinical pharmacology  66(1):27-35. 
42. Stahlhofen W, Koebrich R, Rudolf G, Scheuch G 1990. Short-term and long-term 
clearance of particles from the upper human respiratory tract as function of particle size. Journal 
of aerosol science  21:S407-S410. 
43. Puchelle E, Zahm J, Girard F, Bertrand A, Polu J, Aug F, Sadoul P 1980. Mucociliary 
transport in vivo and in vitro. Relations to sputum properties in chronic bronchitis. European 
journal of respiratory diseases  61(5):254. 
44. Oberdörster G 1988. Lung clearance of inhaled insoluble and soluble particles. Journal of 
Aerosol Medicine  1(4):289-330. 
45. Heyder J, Svartengren MU 2001. Basic principles of particle behavior in the human 
respiratory tract. Lung biology in Health and Disease  162:21-46. 
46. Yang W, Peters JI, Williams RO 2008. Inhaled nanoparticles—a current review. 
International Journal of Pharmaceutics  356(1):239-247. 
47. Sung JC, Pulliam BL, Edwards DA 2007. Nanoparticles for drug delivery to the lungs. 
Trends in biotechnology  25(12):563-570. 
48. Heyder J 2004. Deposition of inhaled particles in the human respiratory tract and 
consequences for regional targeting in respiratory drug delivery. Proceedings of the American 
Thoracic Society  1(4):315-320. 
49. Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W 1986. Deposition of particles 
in the human respiratory tract in the size range 0.005–15 µm. Journal of aerosol science  
17(5):811-825. 
50. Pritchard J 2001. The influence of lung deposition on clinical response. Journal of 
Aerosol Medicine  14(1, Supplement 1):19-26. 
51. Anderson PJ 2005. History of aerosol therapy: liquid nebulization to MDIs to DPIs. 
Respiratory care  50(9):1139-1150. 
52. Chetan M, Negoias A. Advanced Topics in Electrical Engineering (ATEE), 2011 7th 
International Symposium on, 2011, pp 1-4. 
53. Pitance L, Vecellio L, Leal T, Reychler G, Reychler H, Liistro G 2010. Delivery efficacy 
of a vibrating mesh nebulizer and a jet nebulizer under different configurations. Journal of 
aerosol medicine and pulmonary drug delivery  23(6):389-396. 
	   	  
36	  
	  
54. Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, Douglas G, Muers M, 
Smith D, White J. 2001. Comparison of the effectiveness of inhaler devices in asthma and 
chronic obstructive airways disease: a systematic review of the literature. ed.: Core Research. 
55. Smyth HDC 2003. The influence of formulation variables on the performance of 
alternative propellant-driven metered dose inhalers. Advanced Drug Delivery Reviews  
55(7):807-828. 
56. Newman S 2005. Inhaler treatment options in COPD. European Respiratory Review  
14(96):102-108. 
57. Newman SP 2005. Principles of metered-dose inhaler design. Respiratory care  
50(9):1177-1190. 
58. Islam N, Gladki E 2008. Dry powder inhalers (DPIs)—a review of device reliability and 
innovation. International Journal of Pharmaceutics  360(1):1-11. 
59. Chew NYK, Chan HK 2001. Use of solid corrugated particles to enhance powder aerosol 
performance. Pharmaceutical research  18(11):1570-1577. 
60. Chougule MB, Padhi BK, Jinturkar KA, Misra A 2007. Development of dry powder 
inhalers. Recent Patents on drug delivery & formulation  1(1):11-21. 
61. Chew NYK, Bagster DF, Chan HK 2000. Effect of particle size, air flow and inhaler 
device on the aerosolisation of disodium cromoglycate powders. International Journal of 
Pharmaceutics  206(1-2):75-84. 
62. Srichana T, Martin G, Marriott C 1998. Dry powder inhalers: the influence of device 
resistance and powder formulation on drug and lactose deposition in vitro. European journal of 
pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences  
7(1):73. 
63. Coates MS, Fletcher DF, Chan HK, Raper JA 2004. Effect of design on the performance 
of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and 
mouthpiece length. Journal of pharmaceutical sciences  93(11):2863-2876. 
64. MacIntyre NR, Silver RM, Miller CW, Schuler F, Coleman RE 1985. Aerosol delivery in 
intubated, mechanically ventilated patients. Critical care medicine  13(2):81. 
65. Fink JB, Dhand R, Grychowski J, Fahey PJ, Tobin MJ 1999. Reconciling in vitro and in 
vivo measurements of aerosol delivery from a metered-dose inhaler during mechanical 
ventilation and defining efficiency-enhancing factors. American journal of respiratory and 
critical care medicine  159(1):63-68. 
66. Di Paolo ER, Pannatier A, Cotting J 2005. In vitro evaluation of bronchodilator drug 
delivery by jet nebulization during pediatric mechanical ventilation. Pediatric Critical Care 
Medicine  6(4):462-469. 
67. Dhand R, Tobin MJ 1997. Inhaled bronchodilator therapy in mechanically ventilated 
patients. American journal of respiratory and critical care medicine  156(1):3-10. 
68. Chatmongkolchart S, Schettino GPP, Dillman C, Kacmarek RM, Hess DR 2002. In vitro 
evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: 
effect of ventilator settings and nebulizer position. Critical care medicine  30(11):2515-2519. 
69. Ari A, Atalay OT, Harwood R, Sheard MM, Aljamhan EA, Fink JB 2010. Influence of 
nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult 
lung models during mechanical ventilation. Respiratory care  55(7):845-851. 
70. Chiumello D, Pelosi P, Calvi E, Bigatello L, Gattinoni L 2002. Different modes of 
assisted ventilation in patients with acute respiratory failure. European Respiratory Journal  
20(4):925-933. 
	   	  
37	  
	  
71. Thille AW, Rodriguez P, Cabello B, Lellouche F, Brochard L 2006. Patient-ventilator 
asynchrony during assisted mechanical ventilation. Intensive care medicine  32(10):1515-1522. 
72. Sassoon CS, Foster GT 2001. Patient-ventilator asynchrony. Current opinion in critical 
care  7(1):28-33. 
73. Lin S-L, Yeh S-J. Bioinformatics and Biomedical Engineering (iCBBE), 2010 4th 
International Conference on, 2010, pp 1-5. 
74. Bowton DL, Hite RD 2011. 2.3 Ventilator mechanics. Practical Guide to Mechanical 
Ventilation:133. 
75. Yang SC, Yang SP 2002. Effects of inspiratory flow waveforms on lung mechanics, gas 
exchange, and respiratory metabolism in COPD patients during mechanical ventilation. CHEST 
Journal  122(6):2096-2104. 
76. Roth A, Lange C, Finlay W 2003. The effect of breathing pattern on nebulizer drug 
delivery. Journal of Aerosol Medicine  16(3):325-339. 
77. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR 
2005. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic 
obstructive pulmonary disease. American journal of respiratory and critical care medicine  
171(6):591-597. 
78. Fink JB, Dhand R, Duarte AG, Jenne JW, Tobin MJ 1996. Aerosol delivery from a 
metered-dose inhaler during mechanical ventilation. An in vitro model. American journal of 
respiratory and critical care medicine  154(2):382-387. 
79. Ari A, Fink JB 2010. Factors affecting bronchodilator delivery in mechanically ventilated 
adults. Nursing in Critical Care  15(4):192-203. 
80. Dolovich MA 2000. Influence of inspiratory flow rate, particle size, and airway caliber 
on aerosolized drug delivery to the lung. Respiratory care  45(6):597. 
81. Hess DR, Dillman C, Kacmarek RM 2003. In vitro evaluation of aerosol bronchodilator 
delivery during mechanical ventilation: pressure-control vs. volume control ventilation. Intensive 
care medicine  29(7):1145-1150. 
82. Dhand R 2003. Maximizing aerosol delivery during mechanical ventilation: go with the 
flow and go slow. Intensive care medicine  29(7):1041-1042. 
83. Diot P, Morra L, Smaldone GC 1995. Albuterol delivery in a model of mechanical 
ventilation. Comparison of metered-dose inhaler and nebulizer efficiency. American journal of 
respiratory and critical care medicine  152(4):1391-1394. 
84. Duarte AG 2004. Inhaled bronchodilator administration during mechanical ventilation. 
Respiratory care  49(6):623-634. 
85. Miller DD, Amin MM, Palmer LB, Shah AR, Smaldone GC 2003. Aerosol delivery and 
modern mechanical ventilation in vitro/in vivo evaluation. American journal of respiratory and 
critical care medicine  168(10):1205-1209. 
86. Dhand R 2008. Aerosol delivery during mechanical ventilation: from basic techniques to 
new devices. Journal of aerosol medicine and pulmonary drug delivery  21(1):45-60. 
87. Zhu K, Tan RBH, Kiong Ng W, Shen S, Zhou Q, Heng PWS 2008. Analysis of the 
influence of relative humidity on the moisture sorption of particles and the aerosolization process 
in a dry powder inhaler. Journal of Aerosol Science  39(6):510-524. 
88. Chew NYK, Chan HK 2002. The role of particle properties in pharmaceutical powder 
inhalation formulations. Journal of Aerosol Medicine  15(3):325-330. 
	   	  
38	  
	  
89. Minne A, Boireau H, Horta MJ, Vanbever R 2008. Optimization of the aerosolization 
properties of an inhalation dry powder based on selection of excipients. European Journal of 
Pharmaceutics and Biopharmaceutics  70(3):839-844. 
90. Dunbar CA, Hickey AJ, Holzner P 1998. Dispersion and characterization of 
pharmaceutical dry powder aerosols. Kona  16:7-45. 
91. Pornputtapitak W, El-­‐gendy N, Berkland C 2012. Nanocluster budesonide formulations 
enhance drug delivery through endotracheal tubes. Journal of pharmaceutical sciences. 
92. Pornputtapitak W, El-Gendy N, Mermis J, O’Brien-Ladner A, Berkland C 2013. 
NanoCluster budesonide formulations enable efficient drug delivery driven by mechanical 
ventilation. International journal of pharmaceutics. 
93. Dhand R 2000. Special problems in aerosol delivery: artificial airways. Respiratory care  
45(6):636-645. 
94. Crogan SJ, Bishop MJ 1989. Delivery efficiency of metered dose aerosols given via 
endotracheal tubes. Anesthesiology  70(6):1008-1010. 
95. Adair C, Gorman S, Feron B, Byers L, Jones D, Goldsmith C, Moore J, Kerr J, Curran M, 
Hogg G 1999. Implications of endotracheal tube biofilm for ventilator-associated pneumonia. 
Intensive care medicine  25(10):1072-1076. 
96. Berra L, Curto F, Bassi GL, Laquerriere P, Baccarelli A, Kolobow T 2006. Antibacterial-
coated tracheal tubes cleaned with the Mucus Shaver. Intensive care medicine  32(6):888-893. 
97. Shah C, Kollef MH 2004. Endotracheal tube intraluminal volume loss among 
mechanically ventilated patients*. Critical care medicine  32(1):120-125. 
98. Boque M, Gualis B, Sandiumenge A, Rello J 2004. Endotracheal tube intraluminal 
diameter narrowing after mechanical ventilation: use of acoustic reflectometry. Intensive care 
medicine  30(12):2204-2209. 
99. Inglis T, Millar M, Jones J, Robinson D 1989. Tracheal tube biofilm as a source of 
bacterial colonization of the lung. Journal of clinical microbiology  27(9):2014-2018. 
100. Kolobow T, Berra L, Bassi GL, Curto F 2005. Novel system for complete removal of 
secretions within the endotracheal tube: the Mucus Shaver. Anesthesiology  102(5):1063-1065. 
101. Panigada M, Berra L, Greco G, Stylianou M, Kolobow T 2003. Bacterial colonization of 
the respiratory tract following tracheal intubation-Effect of gravity: An experimental study*. 
Critical care medicine  31(3):729-737. 
102. Zhang Z, Kleinstreuer C 2003. Species heat and mass transfer in a human upper airway 
model. International Journal of Heat and Mass Transfer  46(25):4755-4768. 
103. Xi J, Longest PW 2008. Effects of oral airway geometry characteristics on the diffusional 
deposition of inhaled nanoparticles. Journal of biomechanical engineering  130(1):011008. 
104. Zhang Z, Kleinstreuer C 2004. Airflow structures and nano-particle deposition in a 
human upper airway model. Journal of computational physics  198(1):178-210. 
105. Zhang Z, Kleinstreuer C, Donohue J, Kim C 2005. Comparison of micro-and nano-size 
particle depositions in a human upper airway model. Journal of aerosol science  36(2):211-233. 
106. Kleinstreuer C, Zhang Z, Li Z 2008. Modeling airflow and particle transport/deposition 
in pulmonary airways. Respiratory physiology & neurobiology  163(1):128-138. 
107. Longest P, Vinchurkar S, Martonen T 2006. Transport and deposition of respiratory 
aerosols in models of childhood asthma. Journal of aerosol science  37(10):1234-1257. 
108. Kleinstreuer C, Shi H, Zhang Z 2007. Computational analyses of a pressurized metered 
dose inhaler and a new drug-aerosol targeting methodology. Journal of Aerosol Medicine  
20(3):294-309. 
	   	  
39	  
	  
109. Telko MJ, Hickey AJ 2005. Dry powder inhaler formulation. Respiratory care  
50(9):1209-1227. 
110. Shur J, Lee S, Adams W, Lionberger R, Tibbatts J, Price R 2012. Effect of Device 
Design on the In Vitro Performance and Comparability for Capsule-Based Dry Powder Inhalers. 
The AAPS journal:1-10. 
111. Clark A, Hollingworth A 1993. The relationship between powder inhaler resistance and 
peak inspiratory conditions in healthy volunteers—implications for in vitro testing. Journal of 
Aerosol Medicine  6(2):99-110. 
112. Adachi YS, Adachi Y, Itazawa T, Yamamoto J, Murakami G, Miyawaki T 2006. Ability 
of preschool children to use dry powder inhalers as evaluated by In-­‐Check Meter. Pediatrics 
international  48(1):62-65. 
113. Amirav I, Newhouse MT, Mansour Y 2005. Measurement of peak inspiratory flow with 
in-­‐check dial device to simulate low-­‐resistance (Diskus) and high-­‐resistance (Turbohaler) dry 
powder inhalers in children with asthma. Pediatric pulmonology  39(5):447-451. 
114. Janssens W, VandenBrande P, Hardeman E, De Langhe E, Philps T, Troosters T, 
Decramer M 2008. Inspiratory flow rates at different levels of resistance in elderly COPD 
patients. European Respiratory Journal  31(1):78-83. 
115. Jarvis S, Ind PW, Shiner RJ 2007. Inhaled therapy in elderly COPD patients; time for re-
evaluation? Age and ageing  36(2):213-218. 
116. Coates MS, Chan HK, Fletcher DF, Raper JA 2006. Effect of design on the performance 
of a dry powder inhaler using computational fluid dynamics. Part 2: air inlet size. Journal of 
pharmaceutical sciences  95(6):1382-1392. 
117. Georgopoulos D, Mouloudi E, Kondili E, Klimathianaki M 2000. Bronchodilator 
delivery with metered-dose inhaler during mechanical ventilation. Critical Care  4(4):227. 
118. Harvey C, O'Doherty M, Page C, Thomas S, Nunan T, Treacher D 1997. Comparison of 
jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation. 
European Respiratory Journal  10(4):905-909. 
119. Alvine G, Rodgers P, Fitzsimmons K, Ahrens R 1992. Disposable jet nebulizers. How 
reliable are they? CHEST Journal  101(2):316-319. 
120. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM 1996. Medication nebulizer 
performance: effects of diluent volume, nebulizer flow, and nebulizer brand. CHEST Journal  
110(2):498-505. 
121. Loffert DT, Ikle D, Nelson HS 1994. A comparison of commercial jet nebulizers. Chest  
106(6):1788-1792. 
122. Dhand R 2004. New frontiers in aerosol delivery during mechanical ventilation. 
Respiratory care  49(6):666-677. 
123. Ari A, Fink JB, Dhand R 2012. Inhalation Therapy in Patients Receiving Mechanical 
Ventilation: An Update. Journal of aerosol medicine and pulmonary drug delivery. 
124. Rau JL, Hess D 2009. A guide to aerosol delivery devices for respiratory therapists. 
AARC Times:53. 
125. Ari A, Areabi H, Fink JB 2010. Evaluation of aerosol generator devices at 3 locations in 
humidified and non-humidified circuits during adult mechanical ventilation. Respiratory care  
55(7):837-844. 
126. Branconnier MP, Hess DR 2005. Albuterol delivery during noninvasive ventilation. 
Respiratory care  50(12):1649-1653. 
	   	  
40	  
	  
127. Everard M, Devadason S, Summers Q, Le Souef P 1995. Factors affecting total and" 
respirable" dose delivered by a salbutamol metered dose inhaler. Thorax  50(7):746-749. 
128. Everard ML, Devadason SG, Le Souef PN 1996. In vitro assessment of drug delivery 
through an endotracheal tube using a dry powder inhaler delivery system. Thorax  51(1):75-77. 
129. El-­‐Gendy N, Gorman EM, Munson EJ, Berkland C 2009. Budesonide nanoparticle 
agglomerates as dry powder aerosols with rapid dissolution. Journal of pharmaceutical sciences  
98(8):2731-2746. 
130. MacLoughlin RJ, Higgins BD, Laffey JG, O'Brien T 2009. Optimized Aerosol Delivery 
to a Mechanically Ventilated Rodent. Journal of Aerosol Medicine and Pulmonary Drug 
Delivery  22(4):323-332. 
131. Dhand R, Tobin MJ 1997. Inhaled bronchodilator therapy in mechanically ventilated 
patients. American journal of respiratory and critical care medicine  156(1):3. 
132. Dhand R 2005. Inhalation therapy with metered-dose inhalers and dry powder inhalers in 
mechanically ventilated patients. Respiratory care  50(10):1331. 
133. Moraine JJ, Truflandier K, Vandenbergen N, Berr ้ J, M ้lot C, Vincent JL 2009. Placement 
of the nebulizer before the humidifier during mechanical ventilation: Effect on aerosol delivery. 
Heart & Lung: The Journal of Acute and Critical Care  38(5):435-439. 
134. Hu J, Johnston KP, Williams III RO 2004. Nanoparticle engineering processes for 
enhancing the dissolution rates of poorly water soluble drugs. Drug development and industrial 
pharmacy  30(3):233-245. 
135. El-Gendy N, Gorman E, Munson E, Berkland C 2009. Budesonide nanoparticle 
agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci  98(8):2731-2746. 
136. Sinha PK, Misra S 2005. Supraglottic airway devices other than laryngeal mask airway 
and its prototypes. Indian Journal of Anaesthesia  49(4):281. 
137. Alhede M, Jakobsen TH, Givskov M 2011. Novel and Future Treatment Strategies. 
Biofilm Infections:231-249. 
138. Christensson C, Thoren A, Lindberg B 2008. Safety of inhaled budesonide: clinical 
manifestations of systemic corticosteroid-related adverse effects. Drug Safety  31(11):965-988. 
139. Kelly MM, O'Connor TM, Leigh R, Otis J, Gwozd C, Gauvreau GM, Gauldie J, O'Byrne 
PM 2010. Effects of budesonide and formoterol on allergen-induced airway responses, 
inflammation, and airway remodeling in asthma. Journal of Allergy and Clinical Immunology  
125(2):349-356. 
140. El-Gendy N, Aillon KL, Berkland C 2010. Dry powdered aerosols of diatrizoic acid 
nanoparticle agglomerates as a lung contrast agent. International journal of pharmaceutics  
391(1-2):305-312. 
141. Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY 2007. Particle engineering for 
pulmonary drug delivery. Pharmaceutical research  24(3):411-437. 
142. Chougule MB, Padhi BK, Jinturkar KA, Misra A 2007. Development of dry powder 
inhalers. Recent Patent On Drug Delivery & Formulation  1(1):11-21. 
143. Kwok P, Chan H 2008. Effect of relative humidity on the electrostatic charge properties 
of dry powder inhaler aerosols. Pharm Res  25(2):277-288. 
144. Daviskas E, Gonda I, Anderson SD 1990. Mathematical modeling of heat and water 
transport in human respiratory tract. Journal of Applied Physiology  69(1):362. 
145. Raula J, Kurkela JA, Brown DP, Kauppinen EI 2007. Study of the dispersion behaviour 
of L-leucine containing microparticles synthesized with an aerosol flow reactor method. Powder 
Technology  177(3):125-132. 
	   	  
41	  
	  
146. Takaya T, Takeyama K, Takiguchi M 2002. The efficiency of 2-agonist delivery through 
tracheal tubes with the metered-dose inhaler: an in vitro study. Journal of anesthesia  16(4):284-
288. 
147. Louey MD, Van Oort M, Hickey AJ 2006. Standardized entrainment tubes for the 
evaluation of pharmaceutical dry powder dispersion. Journal of Aerosol Science  37(11):1520-
1531. 
148. Broeders MEAC, Molema J, Hop WCJ, Folgering HTM 2003. Inhalation profiles in 
asthmatics and COPD patients: reproducibility and effect of instruction. J Aerosol Med  
16(2):131-141. 
149. Malmberg LP, Rytilä P, Happonen P, Haahtela T 2010. Inspiratory flows through dry 
powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity 
matters. International Journal of Chronic Obstructive Pulmonary Disease  5:257. 
150. Guo C, Gillespie SR, Kauffman J, Doub WH 2008. Comparison of delivery 
characteristics from a combination metered-dose inhaler using the Andersen cascade impactor 
and the next generation pharmaceutical impactor. Journal of pharmaceutical sciences  
97(8):3321-3334. 
151. Dhand R 2007. Inhalation therapy in invasive and noninvasive mechanical ventilation. 
Current opinion in critical care  13(1):27. 
152. Dolovich MB, Dhand R 2011. Aerosol drug delivery: developments in device design and 
clinical use. The Lancet  377(9770):1032-1045. 
153. Martonen TB, Smyth HD, Isaacs KK, Burton RT 2005. Issues in drug delivery: concepts 
and practice. Respiratory care  50(9):1228-1252. 
154. Pornputtapitak W, El-­‐gendy N, Berkland C 2011. Nanocluster budesonide formulations 
enhance drug delivery through endotracheal tubes. Journal of Pharmaceutical Sciences. 
155. Labiris NR, Dolovich MB 2003. Pulmonary drug delivery. Part II: the role of inhalant 
delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. 
British journal of clinical pharmacology  56(6):600-612. 
156. Srichana T, Martin G, Marriott C 1998. Dry powder inhalers: the influence of device 
resistance and powder formulation on drug and lactose deposition in vitro. European Journal of 
Pharmaceutical Sciences  7(1):73-80. 
157. El-Gendy N, Selvam P, Soni P, Berkland C 2012. Development of budesonide 
nanocluster dry powder aerosols: Preformulation. Journal of Pharmaceutical Sciences  
101(9):3434-3444. 
158. Oliyai R, Brewster M, Charman W, Rajewski R, Ozeki T, El-Gendy N, Selvam P, Soni P, 
Berkland C 2012. Development of budesonide nanocluster dry powder aerosols: Preformulation. 
Journal of Pharmaceutical Sciences  101(9):3434-3444. 
159. Sassoon CSH, Foster GT 2001. Patient-ventilator asynchrony. Current opinion in critical 
care  7(1):28. 
160. Haas CF, Bauser KA 2012. Advanced Ventilator Modes and Techniques. Critical Care 
Nursing Quarterly  35(1):27. 
161. Georgopoulos D, Prinianakis G, Kondili E 2006. Bedside waveforms interpretation as a 
tool to identify patient-ventilator asynchronies. Intensive care medicine  32(1):34-47. 
162. Mouloudi E, Prinianakis G, Kondili E, Georgopoulos D 2000. Bronchodilator delivery by 
metered-dose inhaler in mechanically ventilated COPD patients: influence of flow pattern. 
European Respiratory Journal  16(2):263-268. 
	   	  
42	  
	  
163. EVERARD ML 2000. CFC transition: the Emperor's new clothes. Each class of drug 
deserves a delivery system that meets its own requirements. Thorax  55(10):811. 
164. Newman S, Busse W 2002. Evolution of dry powder inhaler design, formulation, and 
performance. Respiratory medicine  96(5):293-304. 
165. Lenney J, Innes J, Crompton G 2000. Inappropriate inhaler use: assessment of use and 
patient preference of seven inhalation devices. Respiratory medicine  94(5):496-500. 
166. Ross DL, Schultz RK 1996. Effect of inhalation flow rate on the dosing characteristics of 
dry powder inhaler (DPI) and metered dose inhaler (MDI) products. Journal of aerosol medicine  
9(2):215-226. 
167. Behara SRB, Kippax P, Larson I, Morton DAV, Stewart P 2011. Kinetics of emitted 
mass--A study with three dry powder inhaler devices. Chemical Engineering Science. 
168. Coates MS, Chan HK, Fletcher DF, Raper JA 2005. Influence of air flow on the 
performance of a dry powder inhaler using computational and experimental analyses. 
Pharmaceutical research  22(9):1445-1453. 
169. Broeders M, Molema J, Vermue N, Folgering HTM 2001. Peak inspiratory flow rate and 
slope of the inhalation profiles in dry powder inhalers. European Respiratory Journal  18(5):780-
783. 
170. Coates MS, Fletcher DF, Chan HK, Raper JA 2005. The role of capsule on the 
performance of a dry powder inhaler using computational and experimental analyses. 
Pharmaceutical research  22(6):923-932. 
171. Chew NYK, Chan HK, Bagster DF, Mukhraiya J 2002. Characterization of 
pharmaceutical powder inhalers: estimation of energy input for powder dispersion and effect of 
capsule device configuration. Journal of Aerosol Science  33(7):999-1008. 
172. Chavan V, Dalby R 2002. Novel system to investigate the effects of inhaled volume and 
rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler. 
The AAPS Journal  4(2):7-12. 
173. Miller DD, Amin MM, Palmer LB, Shah AR, Smaldone GC 2003. Aerosol delivery and 
modern mechanical ventilation. American journal of respiratory and critical care medicine  
168(10):1205-1209. 
174. Van Der Palen J 2003. Peak inspiratory flow through Diskus and Turbuhaler, measured 
by means of a peak inspiratory flow meter (In-Check DIAL®). Respiratory medicine  97(3):285-
289. 
175. Behara SRB, Larson I, Kippax P, Stewart P, Morton DAV 2012. Insight into pressure 
drop dependent efficiencies of dry powder inhalers. European Journal of Pharmaceutical 
Sciences. 
176. BYRON PR 1998. United States Pharmacopeia Recommendations for the Testing of 



















NanoCluster budesonide formulations enhance drug delivery 












Inhalation represents a desirable but largely untapped route for delivering drugs to 
ventilated patients. In this capacity, both nebulizers and pressurized metered-dose inhalers 
(pMDIs) have been widely investigated; however, aerosol delivery in this setting is complex. 
Nebulizers or inhalers must be properly interfaced to efficiently introduce aerosol into the 
ventilator circuit. Aerosols must then successfully navigate the ventilator tubing and an 
endotracheal tube. New formulations or devices are desperately needed to enable drug delivery 
to these patients. 
Liquid formulations currently explored for aerosol delivery in ventilated patients often 
prove ineffective at delivering aerosol to the lungs. Liquid aerosol deposition in the ventilator 
circuit and the endotracheal tube often results in inefficient and variable dosing. In traditional 
nebulization, aerosol droplets exhibit relatively large diameters and a broad size distribution. 
Smaller droplet sizes (~1-3 µm) more efficiently traverse and exit the endotracheal tube 130. 
Larger droplets tend to deposit in the ventilation circuit and on artificial airways such as the 
endotracheal tube by sedimentation or by inertial impaction. Humidification of the ventilator 
circuit can compound this problem by inducing droplet growth. An overly dry circuit, however, 
can affect the airway mucosa 79,86,131-133.  
The development of new formulations is imperative to enhance drug delivery to the lungs 
of patients in critical care. Dry powder formulations can provide improved stability compared to 
liquid formulations. To increase lung coverage, particles should have an aerodynamic diameter 
of 1-5 µm. Although nanoparticles can enhance the dissolution rate of drugs in the lung, 
nanoparticles often agglomerate into irregular sizes during drying and can yield poor dry powder 
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aerosols. Controlling nanoparticle agglomeration provides one attractive formulation option. 
Well-defined nanoparticle agglomerates (NanoClusters) can also prevent cohesion and adhesion 
of powders. Such particles have an irregular surface, thus reducing contact area and lowering 
particle interactions. Nanoparticle agglomerates of poorly water-soluble drugs such as 
budesonide or paclitaxel can enhance the dissolution and improve the aerodynamic properties of 
the drugs 134,135. 
Endotracheal tubes also play an important role in aerosol delivery to ventilated patients. 
These tubes have been designed using non-toxic, non-allergic, and non-reactive materials 136. 
Many materials such as Teflon, nylon, silicon, polyethylene, and synthetic rubber have been used 
to make endotracheal tubes. Currently, commercial endotracheal tubes are typically made of 
polyvinylchloride (PVC). Although tubing surfaces are wet and usually covered with a biofilm 
137, researchers have also considered the use of sleeves during drug delivery. Therefore, clean 
and dry endotracheal tubes were studied here. 
Budesonide is a potent glucocorticoid that has been available in inhaled formulations for 
a long time 138. Inhaled budesonide has been used for the treatment of asthma 139 and chronic 
obstructive pulmonary diseases (COPD) 3. This drug could also be a potent therapy for ventilated 
patients if delivered effectively. Here, a novel formulation based on agglomerated budesonide 
nanoparticles was tested for delivery through Teflon tubes or commercial endotracheal tubes. 
Formulas with or without excipients were compared to micronized stock budesonide and to the 
Pulmicort Flexhaler powder. Variables such as humidity, diameter of endotracheal tubes, and 
volumetric flow rates were investigated. 
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2.2 Materials and methods 
2.2.1 Materials 
Budesonide was generously provided by Savara Pharmaceuticals. Lactose and L-leucine 
were purchased from Sigma Chemicals Co. (St. Louis, MO). Double-distilled water was 
provided by an EASYpure® RODI Barnstead International, Dubuque, Iowa. Hi-Lo® cuffed 
tracheal tubes (PVC) were provided by clinical collaborates, and Teflon tube were purchased 
from Fisher Scientific (Fair Lawn, NJ).   
2.2.2 Methods 
2.2.2.1 Budesonide NanoCluster fabrication 
Budesonide NanoClusters were prepared by milling 5 grams of micronized budesonide in 
200 mL distilled water for 20 hrs. A Netzsch MiniCer Media Mill was operated using YTZ® 
grinding media (0.5 mm, Tosoh Corp.) under an agitation speed of 2772 rpm. Particle size of 
NanoCluster suspensions was determined by dynamic light scattering (Brookhaven Instruments 
Corp., ZetaPALS) at different time intervals during the milling process.  After milling, the 
collected suspension was frozen at -80ºC and lyophilized for ~36 hours to remove all appreciable 
water content (Labconco FreeZone 1). Various excipients were added to some of the milled 
suspensions and homogenized for 30 seconds before freezing and lyophilization. These 
excipients included lactose and L-leucine in drug:excipient ratios of 1:0.01. Lyophilized 
NanoCluster powder was stored in glass bottles under desiccant at room temperature for further 
use. 
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2.2.2.2 Aerosol characterization 
The aerodynamic characteristics of budesonide formulations and commercial budesonide 
were determined using a Tisch Ambient Cascade Impactor (Tisch Environmental, Inc., Village 
of Cleves, OH). Experiments were conducted in a clean room and humidity was controlled by 
using a humidifier with a programmable digital humidistat. Approximately 3-5 mg of each 
powder was placed on wax paper and vacuumed into the tubing upon actuation of a digital valve. 
A pre-separator was also added between the tube and the first stage of the cascade impactor. The 
endotracheal tube was inserted midway through the pre-separator (Figure 2.1). The instrument 
operated at the reported air flow rate for 4 seconds. Both Teflon tubes and commercial 
endotracheal tubes had an inner diameter as specified. For the tube size study, endotracheal tubes 
that had inner diameters of 5.0, 6.5 or 8.0 mm were investigated. 
 
Figure 2.1 A diagram of cascade impactor with a tube. 
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Dry powders deposited on each stage of the impactor were quantified by the difference in 
weight of the plate on each stage before and after running the experiment. The percent emitted 
fraction (%EF), fine particle fractions of the total dose (FPFTD), mass median aerodynamic 
diameter (MMAD), and geometric standard deviation (GSD) were calculated as follows 140. The 
percent emitted fraction (%EF) was calculated as  
                (Eq. 2.1) 
The fine particle fraction of the total dose (FPFTD) was calculated as the percentage of 
aerosolized particles that have aerodynamic diameters below 5.8 µm and the percentage of 
aerosolized particles that have aerodynamic diameters below 3.3 µm according to the following 
equation. 
                     (Eq. 2.2) 
The mass median aerodynamic diameter (MMAD) and the GSD were determined by a 
linear fit of the cumulative percent less than the particle size range by weight plotted on a 
probability scale as a function of the logarithm of the effective cut-off diameter. Geometric 
standard deviation (GSD) was obtained from the following equation: 
                                                                                (Eq. 2.3) 
When dn is the diameter at the nth percentile of the cumulative distribution. 
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2.2.2.3 Particle size and morphology by scanning electron microscopy (SEM) 
The size and morphology of the formulated budesonide powders were evaluated using an 
LEO 1550 field emission scanning electron microscope and compared to that of stock 
budesonide powders.  Prior to imaging, the samples were sputter-coated with gold for 3 min. 
2.2.2.4 HPLC analysis 
The degradation of budesonide formulations have been performed by using Kromasil C8 
column (4.6 mm x 150 mm, 5 µm). A mixture of 45 percents of water and 55 percents of 
acetonitrile was used as mobile phase. The system was operated at flow rate 1.1 mL/min and the 
injection volume was 30 µL. The analysis was monitor at wavelength 244 nm. Budesonide peak 
was showed at the retention time of 4.55 min and the degradation peak was showed at the 
retention time of 2.72 min.  
2.2.2.5 Thermal analysis 
Nanoparticle agglomerates were investigated by differential scanning calorimetry (DSC, 
Q100 Universal V4.3A TA instruments). A small portion (2-3 mg) of the lyophilized dry mass 
was sealed and placed in an aluminum pan and heated at a constant rate of 10 °C/min over a 
temperature range of 25–350 °C for budesonide powder as received, and nanoparticle 
agglomerate formulations. An inert atmosphere was maintained by purging with nitrogen at 50 
mL/min. For TGA, samples weighing 5 ± 2 mg were scanned at a rate of 10 °C/min with a 
nitrogen flow rate of 40 mL/min. 
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2.2.2.6 Statistical analysis 
The results were presented as the mean and the significant differences were evaluated 
using Prism 4 GraphPad Software and assessed by one-way ANOVA followed by Tukey’s 
Multiple Comparison Test. One-tailed unpaired t-test was used for assessing the difference 
between NC-Bud with 1% L-leucine and NC-Bud with 10% L-leucine. A level of confidence of 
p<0.05 was used. 
2.3 Results and discussion 
2.3.1 NanoCluster budesonide formulations 
Budesonide NanoClusters (NC-Bud) were prepared by a wet milling technique. Milling 
techniques can decrease particles to the nanometer range; however, 1-5 µm particles are desired 
for effective drug delivery to the lung. In particular, particles in the range of 1-2 µm are preferred 
to improve lung coverage and to access the alveolar region. If particles are too small (<1 µm), 
they may be exhaled, whereas large particles (>5 µm) can be trapped in the upper airways, 
mouth and throat 6,141. To achieve the desired particle size, nanoparticles were agglomerated to 
form larger structures. 
SEM images showed that budesonide nanoparticles formed micron-sized agglomerates of 
nanoparticles. NC-Bud contained nanoparticles with a diameter of ~150 nm (Figure 2.2). In 
addition, the particle size of stock budesonide was much larger than NC-Bud. As budesonide was 
milled for longer times, particles generally became smaller (Table 2.1). Attrition of the particles 
produced small particles. The high surface area and increased mobility of the nanoparticles were 
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expected to induce agglomeration. As shown in the SEM image of NC-Bud, small particles were 
indeed agglomerated together to form the NanoClusters. 
 
Figure 2.2 SEM images of (A) NanoCluster budesonide formulation and (B) stock budesonide. 
Table 2.1 Budesonide particle size over time during media milling. 
Time Particle size (nm) 
15 min 1299 
30 min 1133 
1 hour 1041 
2 hours 681-1151* 
4 hours 1026-1269* 
8 hours 901 
12 hours 534 
24 hours 670 
* bimodal distribution 
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Cascade impaction was performed to determine the aerosol performance. Powders were 
entrained into Teflon tubes (ID = 6.5 mm) or commercial endotracheal tubes with an inner 
diameter of 6.5 mm. NC-Bud had a smaller mass median aerodynamic diameter (MMAD) 
compared to stock budesonide and Flexhaler powder when applied through a commercial tube 
(Table 2.2). Generally, the MMAD of NC-Bud was smaller than other budesonide powders. The 
aerosolization efficiency was quantified as the percent emitted fraction (%EF) and the percent 
fine particle fraction (%FPF). The %EF of NC-Bud was significantly (p<0.05) higher than stock 
budesonide and Flexhaler powder underscoring the highly efficient aerosolization of 
NanoCluster formulations. Previous studies using a Turbuhaler, reported that only ~20% of the 
dose reached the end of an endotracheal tube 132. NC-Bud showed a higher %FPF<5.8µm than stock 
budesonide (p<0.05) and slightly higher than Flexhaler powder (Table 2.2). The geometric 
standard deviation (GSD) was also smaller for NC-Bud and was in the range of 2.0-3.0 for all 
powders. 
Table 2.2 Cascade impaction of budesonide when applied through a tube (ID = 6.5 mm) at a 
flow rate of 28.3 L/min (Values = Average ± SD). 
Formulation tube % EF % FPF MMAD GSD 
   < 5.8 < 3.3 (µm)  
Stock  Teflon  18.8 ± 7.0 51.5 ± 6.2 29.9 ± 5.9 4.4 ± 0.6 2.7 ± 0.4 
budesonide commercial  14.9 ± 2.7 50.4 ± 1.2 28.4 ± 5.1 4.7 ± 0.1 2.9 ± 0.3 
NC-Bud Teflon  65.1 ± 1.4 73.9 ± 5.4 27.3 ± 7.0 3.2 ± 0.3 2.0 ± 0.2 
 commercial  71.3 ± 1.0 76.5 ± 1.6 31.0 ± 2.9 3.0 ± 0.1 2.2 ± 0.2 
Flexhaler Teflon  18.6 ± 4.0 68.7 ± 2.8 34.9 ± 11.8 3.2 ± 0.5 2.7 ± 0.3 
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2.3.2 Effect of endotracheal tube 
Powders were weighed onto slips of wax paper and entrained into different tubing using 
negative pressure. The Teflon tube and the commercial endotracheal tube showed almost the 
same size distributions (Figure 2.3). The mass median aerodynamic diameter (MMAD) of 
budesonide formulations when using Teflon tubing was not different from the MMAD when 
using a commercial tube (Table 2.2). The percent emitted fraction (%EF), the percent fine 
particle fraction (%FPF) and the geometric standard deviation (GSD) also did not show a 
significant difference when using the different tube types (Table 2.2).  
 
Figure 2.3 The distribution of different budesonide formulations deposited in the cascade 
impactor when applied through an endotracheal tube (ID = 6.5mm) at a flow rate of 28.3L/min 
for (A) stock budesonide and (B) NC-Bud. 
 
The flow ability of stock budesonide and NC-Bud was qualitatively assessed by 
measuring the angle of repose of the powders. The angle of repose was measured after passing 
powders through the tube and compared to the starting powders. Generally, NC-Bud showed a 
smaller angle of repose compared to stock budesonide (Table 2.3). The angle of repose increased 
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for stock budesonide after passing through tubing, suggesting that the tubing may have induced 
cohesion within the powder, perhaps through inductive charging. There was no statistical 
difference when applying powders through a Teflon tube or a commercial tube. 
Table 2.3 Angle of repose of budesonide formulations (Values = Average ± SD). 
Formulation Angle of repose (degrees) 
  Powder Teflon tube PVC tube 
Stock budesonide 49.4 ± 0.5 55.3 ± 0.5 53.8 ± 1.5 
NC-Bud 39.1 ± 1.1 38.6 ± 0.5 41.3 ± 1.0 
 
Another research has studied the effect of electrostatic charging on aerosol performance. 
Mannitol powders were studied at a low flow rate of ~30 L/min. Teflon and PVC tubing were 
used to generate charges on the powder. Researchers found that the initial charges did not 
influence the aerosolization of powders because the air turbulence may also generate charges on 
the powder and have more influence on powder aerosolization. Although different materials 
generated various amounts of charge on the powder depending on the material, the initial charges 
that were generated by the different tubing materials did not affect the aerosol performance of 
drug powders 142.  
2.3.3 Effect of humidity on powder performance 
A humidifier is applied to control the humidity during mechanical ventilation. Some 
studies showed that during mechanical ventilation, high humidity decreased the aerosol 
deposition by around 40% and the size of particles increased 79. Moisture is known to create 
cohesive forces between particles, thus reducing powder dispersion. The aerosolization of 
powders at different humidity can also depend on the physicochemical nature of the drug 
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compounds. Hygroscopic powders commonly absorb moisture in the dispersing air, causing 
capillary force between particles 88 and these powders often show improved dispersion in a dry 
environment 89. Conversely, low humidity can increase static charging of powders 90.  
Some researchers studied the effect of relative humidity (RH) on the properties of two 
inhaled drug products. They found that the relationship between RH and aerosol charging was 
caused in part by the difference in physicochemical properties of the drugs 143. For example, 
terbutaline sulfate, a hygroscopic drug, in Bricanyl® showed decreasing powder charge with 
increasing RH, whereas budesonide, a non-hygroscopic drug, in Pulmicort® carried the highest 
charge at low RH (15% RH) and high RH (90% RH) but carried the lowest charge at 40% RH. 
For budesonide, they inferred that as the moisture adsorption increased, the charges dissipation 
increased, thus increasing the amount of fine particles. At relative humidity higher than 65%, 
powder particles were more difficult to disperse in the airstream since the high moisture 
increased the cohesive force between the particles 88,143. Here, the budesonide powder 
performance was indeed affected by relative humidity. 
NC-Bud performed better at 55% relative humidity (RH) than at 41% RH. A higher 
percent emitted fraction (%EF) and percent fine particle fraction (%FPF) were observed at 55% 
RH in comparison to 41% RH. The mass median aerodynamic diameter (MMAD) of NC-Bud 
was slightly lower at higher relative humidity (Table 2.4) whereas the size distribution was not 
dramatically different (Figure 2.4). These results may be due to electrostatic interactions that 
affected particles at low relative humidity. As a side note, powders that went through an 
endotracheal tube appeared more cohesive than neat powders, although the angle of repose did 
not change substantially (Table 2.3). Thus, electrostatic interactions between aerosol particles 
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and tube surface or between particles may affect aerosolization efficiency by inducing charging 
of the powder during passage through the tube. The hydrophobic nature of budesonide appeared 
helpful in maintaining overall performance at both humidities, which may prove beneficial since 
some moisture is required to prevent drying of the airway mucosa and to minimize 
bronchospastic responses to breathing cold, dry air. For reference, the percent of relative 
humidity can vary depending on the area in the respiratory tract such as 40% in the mouth, 60% 
in the pharynx and around 100% in the deep airways 144.  
Table 2.4 Cascade impaction of budesonide NanoClusters when applied through an endotracheal 
tube (ID = 6.5 mm) at a flow rate of 28.3 L/min at different relative humidities (Values = 
Average ± SD). 
Tube Relative  % EF % FPF MMAD GSD 
  humidity    < 5.8 < 3.3 (µm)    
Teflon tube  41 % 48.0 ± 3.9 60.6 ± 0.9 25.0 ± 3.3 3.9 ± 0.2 2.0 ± 0.1 
 55 % 58.8 ± 8.7 70.8 ± 4.0 28.8 ± 0.2 3.5 ± 0.3 2.1 ± 0.1 
PVC tube 41 % 58.8 ± 2.2 56.5 ± 0.1 20.1 ± 1.6 4.3 ± 0.0 1.9 ± 0.0 
  55 % 68.5 ± 9.5 62.3 ± 3.3 18.4 ± 2.5 3.9 ± 0.2 1.8 ± 0.1 
 
Figure 2.4 The distribution of NanoCluster budesonide formulation (NC-Bud) deposited on the 
cascade impactor when applied through an endotracheal tube (ID = 6.5mm) at flow rate of 
28.3L/min at different relative humidities for (A) Teflon tube and (B) commercial tube. 
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2.3.4 Effect of excipients on aerosol performance 
Lactose and L-leucine were evaluated as excipients for aerosol drug delivery. Lactose is 
an excipient that is commonly used for aerosol formulation. When used as a carrier particle, 
lactose is known to help dispersion of aerosol powders 141. The percent emitted fraction (%EF) of 
NC-Bud with 1% lactose was higher than the % EF of NC-Bud without excipient (p<0.05) 
(Table 2.5). The MMAD of NC-Bud with 1% lactose was 2.9 ± 0.2 µm when applied through a 
Teflon tube. This value was slightly lower than other formulations. On the contrary, when 
applied through a commercial tube, the MMAD of NC-Bud with 1% lactose was 3.4 ± 0.1 µm. 
This was slightly higher than NC-Bud without excipient. Although those differences were small, 
results suggested that lactose and tube materials had a measurable effect on this drug 
formulation.  
Table 2.5 Cascade impaction of different budesonide formulations when applied through an 
endotracheal tube (ID = 6.5 mm) at a flow rate of 28.3 L/min (Values = Average ± SD). 
Formulation % EF % FPF MMAD GSD 
  < 5.8 < 3.3 (µm)   
NC-Bud w/o excipients 65.1 ± 1.4 73.9 ± 5.4 27.3 ± 7.0 3.2 ± 0.3 2.0 ± 0.2 
NC-Bud w/ 1% lactose 74.5 ± 2.1 71.8 ± 1.4 35.2 ± 2.7 2.9 ± 0.2 2.3 ± 0.2 
NC-Bud w/ 1% L-leucine 72.6 ± 5.8 64.7 ± 3.3 27.3 ± 0.6 3.7 ± 0.2 2.1 ± 0.0 
Stock budesonide 18.8 ± 7.0 51.5 ± 6.2 29.9 ± 5.9 4.4 ± 0.6 2.7 ± 0.4 
Flexhaler powder 18.6 ± 4.0 68.7 ± 2.8 34.9 ± 11.8 3.2 ± 0.5 2.7 ± 0.3 
* Teflon tube 
Formulation % EF % FPF MMAD GSD 
  < 5.8 < 3.3 (µm)   
NC-Bud w/o excipients 71.3 ± 1.0 76.5 ± 1.6 31.0 ± 2.9 3.0 ± 0.1 2.2 ± 0.2 
NC-Bud w 1% lactose 77.8 ± 3.1 67.2 ± 2.9 27.2 ± 1.4 3.4 ± 0.1 2.1 ± 0.0 
NC-Bud w 1% L-leucine 66.9 ± 2.0 66.0 ± 1.4 24.3 ± 0.2 3.7 ± 0.1 1.9 ± 0.0 
Stock budesonide 14.9 ± 2.7 50.4 ± 1.2 28.4 ± 5.1 4.7 ± 0.1 2.9 ± 0.3 
Flexhaler powder 17.7 ± 2.4 56.4 ± 5.3 30.6 ± 3.6 4.1 ± 0.6 2.6 ± 0.1 
* Commercial tube 
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Some researchers have found that L-leucine can also improve powder dispersion. For 
example, L-leucine was shown to improve the dispersion of aerosol particles even if the applied 
flow rate was low 145. The MMAD of NC-Bud with 1% L-leucine was around 3.7 µm when 
applied through a Teflon tube or a commercial tube (Table 2.5). This was slightly higher than 
NC-Bud without excipient and NC-Bud with 1% lactose. Different tubes did not affect the 
performance of these powders. NC-Bud formulations, with or without excipients showed 
substantially better performance when compared to stock budesonide or Flexhaler powders 
(Figure 2.5). SEM images of NC-Bud powders with excipients appeared similar to powders 
without excipient (Figure 2.6). 




Figure 2.5 The distribution of different budesonide formulations deposited in the cascade 
impactor when applied through an endotracheal tube (ID = 6.5mm) at a flow rate of 28.3L/min 
for (A) Teflon tube and (B) commercial tube. 




Figure 2.6 SEM images of (A) budesonide with 1% lactose, and (B) budesonide with 1% L-
leucine. 
 
2.3.5 Effect of endotracheal tube diameter 
The endotracheal tube has been found to affect aerosol delivery during mechanical 
ventilation. Some studies found that a smaller internal diameter tube reduced the efficiency of 
aerosol drug delivery 79,146. The largest diameter endotracheal tube has been suggested to 
overcome the problem of biofilm and secretions that collect in the endotracheal tube 79. It should 
be noted that these studies applied the drug aerosol in the form of liquid aerosol via nebulizers or 
pMDIs.  
Aerosol deposition and distribution of powders changed when applied through 
endotracheal tubes with different internal diameters (ID). Here, different diameter endotracheal 
tubes were studied at the same volumetric flow rate of 28.3 L/min, for 4 seconds. When NC-Bud 
was applied through the 5.0-mm ID tube, the distribution shifted to a smaller size when 
compared to NC-Bud applied through 6.5-mm ID and 8.0-mm ID tubes (Figure 2.7). The 
MMAD when applied through a 5.0-mm tube was lower than the MMAD for the 6.5-mm tube 
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and for the 8.0-mm tube, respectively (Table 2.6). %EF and %FPF also followed this trend. The 
%EF and %FPF increased when the tube size decreased. 
Table 2.6 Cascade impaction of NC-Bud with 1% L-leucine when applied through different 
sizes endotracheal tubes (Values = Average ± SD) at a flow rate of 28.3 L/min. 
Tube % EF % FPF MMAD GSD 
Diameter  < 5.8 < 3.3 (µm)  
5.0 mm 77.1 ± 1.3 78.0 ± 3.1 41.3 ± 4.2 2.5 ± 0.2 2.4 ± 0.1 
6.5 mm 66.6 ± 1.5 64.8 ± 2.3 24.9 ± 1.0 3.7 ± 0.0 2.0 ± 0.1 
8.0 mm 65.5 ± 6.0 57.0 ± 2.4 23.7 ± 6.0 4.2 ± 0.2 2.2 ± 0.4 
 
 
Figure 2.7 The distribution of NC-Bud with 1% L-leucine deposited in the cascade impactor for 
different tube sizes (commercial tube). 
 
At the same flow rate, a smaller tube would yield more turbulent flow in the tube. 
Consequently, shear force in the air flow would increase. Turbulent or laminar flow can be 
described by the Reynolds number (Re). Re is a dimensionless number representing the 
relationship between inertial forces and viscous forces 147. 
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                (Eq. 2.4) 
Here, ρ is the density of air (1.20 kg/m3 at 20 °C), ν is the linear velocity (m/sec), d is the 
diameter of the tube (m), µ is the dynamic viscosity of air (1.81 × 10−5 kg/(m.sec) at 20 °C), Q is 
the volumetric flow rate (m3/sec) and A is the tube cross-sectional area (m2). Since the same flow 
rate was applied, differences between endotracheal tubes depended on the ratio of d and A or 
when simplified d-1. Of course, the 5.0-mm ID tube provided a larger value of d-1 in comparison 
with 6.5-mm ID tubes and 8.0-mm ID tubes, respectively. The Reynolds numbers of 5.0-mm, 
6.5-mm and 8.0-mm tube were 8440, 6460, and 5250, respectively, under the conditions studied. 
All values were in the turbulent flow region (Re>4000). 
2.3.6 Effect of flow rate on powder performance 
In dry powders, the inspiratory flow rate often plays an important role in powder 
performance. A minimum inspiratory flow rate can be required to initiate drug delivery through 
the inhaler and increasing the flow rate can change the performance 148,149. Some studies found 
that powders show better dispersibility when the volumetric flow rates from 15 to 90 L/min were 
applied. They suggested that this flow rate range enhanced the amount of the dispersed fine 
particles and improved deagglomeration of the particles 145. Increasing volumetric flow rate will 
commonly improve the %EF and/or reduce the MMAD. In previous studies, powders showed 
smaller MMAD when applied at a higher flow rate. On the other hand, particles were suspected 
to have a higher velocity at the higher volumetric flow rate, which increased the amount of 
particles that deposited in the induction port (including the USP throat, the glass sampling 
chamber and the pre-separator) 150.  
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The influence of flow rate on shear may be considered in a similar manner as tubing 
diameter, which in this case is ID = 6.5 mm. When applying a high volumetric flow rate, the air 
flow has a higher velocity, resulting in higher shear force. The Reynolds number equation is 
directly affected by the volumetric flow rate (Q). The Reynolds number at volumetric flow rates 
of 30 L/min, 60 L/min and 90 L/min are 6460, 12900, and 19400, respectively. Hence, drug 
powders deagglomerated when applied at higher flow rates. The MMAD of powders at 30 
L/min, 60 L/min and 90 L/min were 3.5 ± 0.3, 1.6 ± 0.1 and 0.7 ± 0.1 µm, respectively (Table 
2.7). In addition, the %FPF increased as the flow rate increased, as expected 88,145,150. The 
distribution shifted toward a smaller MMAD (Figure 2.8).  
Table 2.7 Cascade impaction of NC-Bud with 1% L-leucine when applied through an 
endotracheal tube (commercial tube, ID = 6.5 mm) at different flow rates (Values = Average ± 
SD). 
Flow rate % EF % FPF MMAD GSD 
(L/min)  < 5.8 < 6.5 < 3.3 (µm)   
30 74.1 ± 4.8 66.9 ± 4.5 - 29.3 ± 3.4 3.5 ± 0.3 2.3 ± 0.4 
60 70.3 ± 3.9 - 88.8 ± 2.3 61.6 ± 3.4 1.6 ± 0.1 2.4 ± 0.1 














Figure 2.8 The distribution of NC-Bud with 1% 
L-leucine deposited in the cascade impactor 
when applied through an endotracheal tube 
(Teflon tube, ID = 6.5 mm) at different flow rates 
of (A) 30 L/min, (B) 60 L/min, and (C) 90 
L/min. 
Generally, the %FPF is low not only for large particles but also due to cohesive small 
particles. The latter can be partially reduced by applying a higher volumetric flow rate to 
increase the shear force in the airstreams. Normally, the flow rate influences the %FPF of drug 
powders, especially in commercial inhalers that have low dispersion efficiencies. For example, 
2.7 µm cohesive mannitol powders had a maximal %FPF when delivered from the Rotahaler® at 
a flow rate of 120 L/min, whereas the maximal %FPF can be achieved at ≥ 60 L/min for the 
Dinkihaler®, which has a higher dispersion efficiency 88. Furthermore, the effect of flow rate 
depended on the physicochemical properties of drug powders. For instance, 5 µm mannitol 
delivered from the Rotahaler® had a maximal %FPF when applied at 60 L/min but the flow rate 
had no effect for more cohesive particles of the same particle size 88.   
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Since the performance of these formulations depends on the flow rate, it will be 
important to control the inspiration flow rate during mechanical ventilation. Drug powders that 
are introduced to the patient’s lung at different flow rates may yield a difference in distribution 
or therapeutic effect. At the low flow rate, drug powder may primarily deposit in bronchi and 
achieve a local effect. If the inspiration flow rate is high, NanoCluster particles may be 
deagglomerated into small, ~1 µm primary particles. One potential concern is the inertial 
impaction of these small, high velocity particles, although the velocity would slow as the 
particles entered the trachea. The performance of NanoCluster formulations will ultimately need 
to be synergized with ventilator control parameters to optimize delivery to patients.  
2.4 Conclusion     
NanoCluster formulations of budesonide prepared by a wet-milling technique 
substantially improved aerosol performance compared to stock budesonide and Pulmicort 
Flexhaler powders when applied through an endotracheal tube. In general, excipients such as 
lactose and L-leucine slightly enhanced aerosol properties. Interaction between particles and tube 
materials was expected to affect delivery efficiency. Budesonide formulations did not differ, 
however, when applied through a Teflon tube or a commercial endotracheal tube. Volumetric 
flow rate and tube diameters exhibited a substantial effect on aerosol performance metrics. A 
higher volumetric flow rate and smaller tube diameter dramatically increased the fine particle 
fraction, probably due to deagglomeration of the powder as shear force increased. NanoCluster 
formulations of budesonide represent a potential engineered particle approach for introducing 
dry powder aerosols to ventilated particles.  
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3.1 Introduction  
 Inhaled drugs are delivered to the lungs via three kinds of aerosol generators; nebulizers, 
pressurized metered-dose inhalers (pMDIs), or dry powder inhalers (DPIs). Nebulizers and 
pMDIs are often not efficient in delivering liquid aerosols to patients on mechanical ventilation. 
A common barrier of drug delivery is the loss of drug aerosols in the humid ventilator circuit and 
on the endotracheal tube. DPIs have become a popular option for asthma therapy and have been 
adapted to deliver dry powder formulations to ventilated patients. Optimization of dry powder 
aerosols and devices, however, is still required to realize the potential of this drug delivery 
scheme for ventilated patients. 
 Nebulizers and pMDIs have been historically used during mechanical ventilation. The 
relative lung deposition efficiencies of different nebulizers and pMDIs have been conducted in 
many in vitro and in vivo studies 79. In vitro studies have been highly inconsistent showing 
highly variable quantities of inhaled drug dose when delivered using either nebulizers or pMDIs. 
Most liquid formulations have shown poor efficiency because of inertial impaction or 
gravitational sedimentation of droplets resulting in loss of drug in the ventilator circuit and the 
endotracheal tube. For example, a study showed a considerable percent of drug was deposited in 
the spacer chamber, the ventilator circuit and the endotracheal tube when a pMDI was applied 
151. In addition, the humid environment of the ventilator circuit can cause liquid aerosol droplets 
to increase in size or condense on tubing. 
Dry powder inhalers (DPIs) offer an alternative for delivering drugs into ventilated 
patients. Although many DPIs are available for the treatment of asthma and chronic obstructive 
pulmonary disease (COPD) 152, few of them have been successfully applied to mechanical 
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ventilation. Everard et al. used a modified Turbuhaler with the ventilator circuit. The outer 
covering of the Turbuhaler was removed and the inner cylinder was enclosed to provide spiral 
disaggregation channels in a chamber. Once the device was loaded, air flowing through the 
chamber carried the aerosol to the endotracheal tube. They reported that approximately 20% of 
the nominal dose was delivered to a filter placed at the distal end of the tube 128.  
DPIs on the market are passive devices. The fluidization and aerosolization of drug 
powder in DPIs depends on the inspiratory effort of patients. Some studies indicated that higher 
airflow dependence might result in higher dose variability due to differences in the patients’ 
inspiration effort 153. In ventilated patients, however, a patient’s inspiration is mainly controlled 
by the ventilator. Since breathing can be tightly controlled, drug formulations and devices are 
primary design metrics that would influence DPI performance.  
The size and geometry of drug particles play an important role in aerosol performance. 
To improve deposition in the central airways and peripheral areas in the lungs, drug particles 
should be in the size range of 1-5 µm. Since cohesive and adhesive forces influence the 
dispersion of particles in these size ranges, drug formulations should be engineered to reduce 
interactions between particles and interactions with the surface of the inhaler. NanoCluster 
budesonide (NC-Bud) was previously shown to enhance drug delivery through endotracheal 
tubes 154. The preliminary success of NC-Bud formulations compelled additional studies to 
assess performance when inspiration is controlled by a ventilator.  
Besides drug formulation, device design is another factor that affects drug delivery 
through a ventilator circuit. A large variability of emitted dose among different DPIs has been 
reported 155. The design of DPIs for patients on mechanical ventilation has not been well studied. 
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Here, a novel device was designed in order to enhance drug delivery and be convenient to 
connect between the ventilator circuit and the endotracheal tube. The combination of engineered 
dry powders and a novel device design was expected to improve drug delivery efficiency during 
mechanical ventilation. The effect of other parameters such as humidity, air flow rate and 
inspiration pattern were also investigated.  
3.2 Materials and methods 
3.2.1 Materials 
Budesonide (Bud) was obtained from Sicor de Mexico (Lerma,Mexico). Double-distilled 
water was provided by an EASYpure® RODI Barnstead International, Dubuque, Iowa. Hi-Lo® 
cuffed tracheal tubes (PVC) and endotracheal catheter tubes (Kimberly-Clark) were provided by 
clinical collaborators. The ventilator model was 7200® Series Ventilator System (Puritan-Bennett 
Corporation, Carlsbad, CA). The details of Monodose® inhaler (Plastiape Monodose Inhaler 
RS01 Model 7) and the novel device are reported in Table 3.1 and in Figure 3.1.  
Table 3.1 Dimensions of the Monodose® inhaler and the novel device. 
Device Device Mesh size Inlet opening outlet opening 
 geometry (mm) (mm) (mm) 
Monodose® inhaler cylinder 1.28 ± 0.03 4.00x5.66 10.72 
Novel device cylinder 0.15 ± 0.05 2.5 15 
 




Figure 3.1 Photographs of (A) the modified Monodose® inhaler and (B) the novel device.  
 
3.2.2 Methods 
3.2.2.1 Budesonide NanoCluster fabrication 
Budesonide NanoClusters were prepared by milling 5 grams of micronized budesonide in 
200 ml distilled water for 20 hrs. A Netzsch MiniCer Media Mill was operated using YTZ® 
grinding media (0.5 mm, Tosoh Corp., Tokyo, Japan) under an agitation speed of 2772 rpm. 
Particle size of the suspensions was determined by dynamic light scattering (Brookhaven 
Instruments Corp., ZetaPALS) at different time intervals during the milling process. After 
milling, the collected suspension was frozen at -80ºC and lyophilized for ~36 hours to remove all 
appreciable water content (VirTis Feezemobile-12XL, The Virtis Company,Gardiner, 
NewYork). Lyophilized powder was stored in glass bottles under desiccant at room temperature 
for further use.  
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3.2.2.2 Aerosol characterization 
The aerodynamic characteristics of budesonide formulations and commercial budesonide 
were determined using a Tisch Ambient Cascade Impactor (Tisch Environmental, Inc., Village 
of Cleves, OH). Approximately 5 mg of each powder was filled in a capsule (HPMC type, size 3, 
generously provided from Capsugel®, NJ, USA). Powder was introduced to the cascade impactor 
via a modified Monodose® inhaler or a novel dry powder inhaler. Conditions and parameters 
such as volumetric flow rate were controlled by a ventilator. The endotracheal tube was placed 
between the ventilator and the cascade impactor (Figure 3.2).  
 
Figure 3.2 A schematic diagram of the DPI connected between the ventilator and the cascade 
impactor. 
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Dry powders deposited on each stage of the impactor were quantified by the difference in 
weight of the plate on each stage before and after running the experiment. For the humidity 
study, the amounts of drug in each stage were determined by ultraviolet-visible (UV-Vis) 
spectroscopy. The percent emitted fraction (%EF), fine particle fractions of the emitted dose 
(FPFED), mass median aerodynamic diameter (MMAD), and geometric standard deviation (GSD) 
were calculated as previously reported 154. The fine particle fraction of the emitted dose (FPFED) 
was calculated as the percentage of aerosolized particles that have aerodynamic diameters below 
5.8 µm and the percentage of aerosolized particles that have aerodynamic diameters below 3.3 
µm (Eq. 3.1). The %FPFED was calculated as  
            (Eq. 3.1) 
The mass median aerodynamic diameter (MMAD) was determined at the 50th percentile 
of the cumulative mass distribution curve. Geometric standard deviation (GSD) was calculated 
as the square root of the ratio of diameters at the percentile of 84.13% and 15.87% of the 
cumulative distribution 135. 
3.2.2.3 Evaluation of particle size and morphology by scanning electron microscopy (SEM) 
The size and morphology of the formulated budesonide powders were evaluated using an 
LEO 1550 field emission scanning electron microscope and compared to that of stock 
budesonide powders.  Prior to imaging, the samples were sputter-coated with gold for 3 min. 
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3.2.2.4 Ultraviolet-visible (UV-Vis) spectroscopy analysis 
The amount of drug in each stage was determined by an Agilent 8453 UV-Vis 
Spectroscopy System (Agilent Technologies 95-03, Waldbronn, Germany). The instrument was 
equipped with a quartz cell with a path length of 0.1 cm. The measurement was made at a 
wavelength of 244 nm.  
3.2.2.5 Measurement of pressure drop across the devices 
 The pressure drop of the devices was measured using critical flow controller (CFC) (type 
TPK 2000, Copley Scientific, Nottingham, UK). The CFC was connected to a vacuum pump and 
a Dosage Unit Sampling Apparatus (DUSA) (Figure 3.3). The pressure drops were measured at 
flow rates of 30, 60, and 90 L/min. The square root of the pressure drop at different flow rates 
was plotted against the flow rate. The slope of the fitted line was the resistance of the device 156.  
 
Figure 3.3 Experimental set-up for pressure drop measurement. 
 
3.2.2.6 Statistical analysis 
The results were presented as the mean and the significant differences were evaluated 
using Prism 4 GraphPad Software and assessed by one-way ANOVA followed by Tukey’s 
Multiple Comparison Test. One-tailed unpaired t-test was used for assessing the differences 
between NanoCluster budesonide and budesonide as received, modified Monodose® inhaler and 
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new dry powder inhaler, ventilator and ventilator bag, and one-time respiration and three-time 
respiration. A level of confidence of p<0.05 was used for all statistic tests. 
3.3 Results and discussion 
In patients who have problems of breathing, mechanical ventilation is often necessary to 
assist or control respiration. Here, a ventilator was used to provide and control airflow in the 
circuit. Cascade impaction was performed to determine aerosol and DPI performance. A cascade 
impactor was connected to a ventilator and the Monodose®. DPI was integrated as shown (Figure 
3.2). Parameters such as flow rate, inspiratory volume, inspiration pattern, and humidity were 
controlled by the ventilator.  
3.3.1 NanoCluster budesonide (NC-Bud) formulation  
Scanning electron microscopy images showed the increased surface area in nanoparticle 
agglomerates (NanoClusters) of budesonide compared to stock micronized budesonide (Figure 
3.4). NanoCluster budesonide (NC-Bud) formulations previously showed effective performance 
on the cascade impactor when pulled through an endotracheal tube using negative pressure. The 
studies demonstrated that NC-Bud did not require excipients to achieve excellent aerosol 
performance 154,157. NC-Bud without excipients was studied here and these studies were extended 
to ventilator control (positive pressure). 




Figure 3.4 SEM images of (A) NanoCluster budesonide (NC-Bud) and (B) Stock budesonide 
(Scale bar equals to 1 µm). 
 
NC-Bud without excipients and stock budesonide were delivered via a Monodose® 
inhaler through an endotracheal tube (5.0 mm ID). The drug aerosol was delivered by fitting the 
Monodose® inside an aerosolization chamber attached to the end of an endotracheal tube (Figure 
3.2). The ventilator was operated at 30 L/min for one inspiration cycle controlled by the 
ventilator. An inspiratory volume of 2.5 L and sine-wave-form inspiration pattern were applied. 
The NC-Bud showed a percent emitted fraction (%EF) much higher than the %EF of stock 
budesonide (Table 3.2) although the mass median aerodynamic diameter (MMAD) was not 
different between NC-Bud and stock budesonide (p<0.05). The percent fine particle fraction 
(%FPF) of NC-Bud and stock budesonide were 85.2 ± 3.3 and 72.8 ± 12.3, respectively. It 
should be noted that %FPF is calculated as a percentage of the emitted dose, which was quite 
small for stock budesonide. The geometric standard deviation (GSD) of NC-Bud was 2.4, 
smaller than the GSD of stock budesonide (3.6) (Figure 3.5). 
 
(A) (B) 
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Table 3.2 Cascade impaction results of budesonide when applying through an endotracheal tube 
(ID = 5.0 mm) at a flow rate of 30 L/min (Values = Average ± SD). 
Formulation % EF % FPF MMAD GSD 
   < 5.8 < 3.3 (µm)  
NC-Bud 64.6 ± 7.3 85.2 ± 3.3 48.8 ± 6.6 2.2 ± 0.3 2.4 
Stock budesonide 15.9 ± 3.3 72.8 ± 12.3 52.1 ± 12.7 2.1 ± 0.8 3.6 
 
 
Figure 3.5 The distribution of different budesonide formulations deposited on the cascade 
impactor when applied through an endotracheal tube (ID = 5.0 mm) at a flow rate of 30.0 L/min 
for NC-Bud and stock budesonide. 
 
3.3.2 Effect of inspiration pattern, flow rate, and inspiratory volume on powder 
performance  
In patients who cannot aid in respiration, the ventilator will fully control breathing. When 
using assisted modes on the ventilator, mismatching ventilator air delivery and patient inspiration 
causes patient-ventilator asynchrony and can cause injury 159,160. Furthermore, the relationship 
between the ventilator operation and patient inspiration affects ventilation efficiency. Since the 
value of peak inspiratory flow depends on waveforms, a specific waveform may influence the 
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success of mechanical ventilation 161. The basic waveforms can be categorized into three 
patterns; square, ramp and sine wave 74. Some studies showed that the sinusoidal or ramp 
waveforms delivered drug aerosols more effectively than the square waveform 79. They 
suggested that the different inspiration pattern affected the sudden onset and duration of peak 
flows, and the turbulence. Other studies showed the influence of inspiration flow patterns on 
aerosol drug delivery when the drug was delivered via nebulizer compared to pMDI 81. Flow 
patterns influenced albuterol delivered via nebulizer but there was no difference when delivered 
via pMDI. Other studies consistently showed no effect of the flow patterns during bronchodilator 
delivery by pMDI 78,162. Nevertheless, the influence of inspiration flow pattern on aerosol drug 
delivery via dry powder inhalers (DPIs) should be investigated.  
As mentioned previously, DPIs are preferred to pMDIs due to ease of use and the absence 
of propellant163-165. In general, the efficiency of DPIs has depended on the inspiration effort of 
the patient and the resistance in the inhalers. DPI performance is typically flow dependent 166. 
For example, three different dry powder inhalers (Rotahaler®, Monodose® and Handihaler®) 
were studied at various flow rates (30-180 L/min). The emitted mass of salbutamol sulphate 
increased with flow rates when using the Monodose® inhaler. For Rotahaler® and Handihaler®, 
the emitted mass increased with flow rates until it reached a plateau at 60 L/min. The variability 
of emitted mass also decreased with increasing flow rate. The Monodose® showed less 
variability in emitted mass compared to other inhalers due to a different mechanism of capsule 
emptying 167. A computational study of fluid dynamics showed that increasing flow rate 
generated higher turbulence in the device. The turbulence has an effect on fine particle 
dispersion. Although the high flow rate can increase de-agglomeration of powders, it can also 
increase powder impaction 168. Beside inspiration pattern, therefore, in order to optimize drug 
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delivery efficiency in ventilated patients, the effect of inspiratory flow rate must also be 
considered especially considering that ventilators apply a positive pressure to control breathing 
169. 
The aerosol powder was applied through the endotracheal tube (ID = 5.0 mm) at different 
volumetric flow rates for one cycle of inspiration. Three inspiration flow patterns (square, ramp, 
and sine waveforms) were applied. Moreover, since patients with COPD have low inspiratory 
capacity 77, the different lung volumes may lead to variable efficiency of drug delivery to these 
patients. The maximum inspiratory volume on the ventilator used here was 2.5 L. Different 
inspiratory volumes of 1.5, 2.0 and 2.5 L were studied. 
The results showed that the %EF of NC-Bud at flow rate of 20-40 L/min was consistently 
around 70-80% and it did not vary with inspiration patterns. The powder performance was not 
significantly different (p<0.05) for volumetric flow rates in the range of 20 – 40 L/min although 
the %FPF of NC-Bud at a flow rate of 40 L/min was slightly higher than the %FPF at lower flow 
rates (p<0.05). The %FPF was around 80-90% at the cut off diameter of 5.8 µm and around 50% 
at the cut off diameter of 3.3 µm. The MMAD of NC-Bud at a flow rate of 40 L/min was 1.9 µm 

















Table 3.3 Cascade impaction results of NC-Bud when applying with different inspiration 
patterns, different flow rates, and different inspiration volumes (Values = Average ± SD). 
 
Inspiration pattern % EF % FPF MMAD GSD 
    < 5.8 < 3.3  (µm)   
Square waveform 78.9 ± 3.8 82.6 ± 2.3 51.5 ± 3.6 2.0 ± 0.2 2.6 ± 0.0 
Ramp waveform 76.1 ± 8.2 83.5 ± 4.0 49.6 ± 1.4 2.1 ± 0.1 2.5 ± 0.2 
Sine waveform 77.8 ± 10.0 83.5 ± 3.7 49.7 ± 2.6 2.1 ± 0.1 2.4 ± 0.1 
Flow rate  % EF % FPF MMAD GSD 
 (L/min)   < 5.8 < 3.3 (µm)    
20 72.4 ± 5.4 83.8 ± 1.0 51.2 ± 0.8 2.1 ± 0.1 2.4 ± 0.1 
30 77.8 ± 10.0  83.5 ± 3.7 49.6 ± 2.6 2.1 ± 0.1 2.4 ± 0.1 
40 75.6 ± 5.8 90.2 ± 0.7 55.8 ± 2.1 1.9 ± 0.1 3.0 ± 0.1 
Volume  % EF % FPF MMAD GSD 
 (L)   < 5.8 < 3.3 (µm)    
1.5 74.6 ± 7.7 84.8 ± 2.9 48.8 ± 2.1 2.2 ± 0.1 2.5 ± 0.1 
2.0 79.8 ± 3.2  84.3 ± 2.6 48.0 ± 4.0 2.2 ± 0.2 2.5 ± 0.3 
















Figure 3.6 The distribution of NC-Bud 
deposited on the cascade impactor when 
applied through an endotracheal tube (ID = 
5.0 mm); (A) with different inspiration 
patterns; square waveform, ramp waveform 
and sine waveform, (B) at different flow 




Also, the same %EF, %FPF, MMAD and GSD were achieved for the study of the 
different volumes. Studies investigating the role of capsules on the inhaler performance 
suggested that, although the size of the capsule has an insignificant effect on inhaler 
performance, the capsule-particle impaction could play a role in the de-agglomeration 
mechanism depending on the size of the capsule hole 170,171. Here, the same inhaler and the same 
size of capsules were applied to all experiments. A study that evaluated the effect of inhaled 
volume on dry powder inhalers showed that the inhaled volumes can have no significant effect 
on fine particle fraction (FPF) at flow rates of 30 and 60 L/min 172. It is likely, therefore, that the 
(A) (B) 
(C) 
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time for emptying the capsule was shorter than the time required for delivering 1.5 L of air or 
more through the cascade impactor.  
3.3.3 Effect of humidity of inspiratory airflow on powder performance 
Traditionally, liquid aerosols are used in mechanically ventilated patients. The efficiency 
of aerosol delivery is affected by humidity of inspired air and by humidity in the circuit65,78,173. In 
one study 173, albuterol was delivered via nebulizers through an endotracheal tube. The size of 
aerosol droplets increased when the humidifier was applied due to hygroscopic growth. A greater 
impaction in the ventilator tubing decreased the total aerosol delivery as humidity increased. An 
in vivo study delivering antibiotics to patients showed higher sputum levels (sputum levels 
provide a direct index of drug delivery) in a non-humidified ventilator compared to humidified 
173. Similarly, albuterol delivered via pMDIs showed lower percent drug delivery in a humidified 
circuit due to impaction in the ventilator circuit 78.  Therefore, humidity is an important 
parameter that affects the efficiency of drug delivery during mechanical ventilation.  
Besides liquid aerosol delivery, relative humidity can have an effect on dry powder 
aerosol delivery. The efficiency of drug delivery can be decreased in both dry and humid 
environments 87. At high humidity, capillary force between the particles can decrease drug 
delivery efficiency. Moisture can create cohesive forces between particles, decreasing powder 
dispersion 88,89. Conversely, static charges between the particles play a role in powder dispersion 
at low humidity 90. Furthermore, each drug has a different physicochemical nature (i.e. 
hygroscopicity). 
Budesonide is a relatively non-hygroscopic drug, yet the powder performance depends on 
the humidity. At low relative humidity (RH), budesonide particles were reported to carry static 
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charge. That charge can be dissipated when the RH increases; however, if the %RH was higher 
than 65, the dispersion of budesonide was decreased due to cohesive forces between particles 
88,90. NanoCluster budesonide (NC-Bud) was previously investigated under 2 conditions of 
relative humidity (41% and 55%). The results showed that the formulations performed better at 
the higher %RH 154. Here, the ventilator was used to control the percent relative humidity at 
around 51 and 82% (under operating of the humidifier, the equilibrated humidity in the circuit 
was 82%). 
The NC-Bud aerosol was delivered as before (Monodose® inhaler, 5.0 mm endotracheal 
tube, 30 L/min). The sine wave form and the inspiratory volume of 2.5 L were applied for all 
experiments. The %EF of NC-Bud when operated at 82% was lower than the %EF of NC-Bud 
when operated at 51% RH (p<0.05) although the distribution of aerosol powder at 51 and 82% 
RH were the same (Figure 3.7). The MMAD at 51% and 82% RH were 2.2 ± 0.3 and 2.1 ± 0.1, 
respectively (Table 3.4).  
Table 3.4 Cascade impaction results of NC-Bud when applying through an endotracheal tube 
(ID = 5.0 mm) at different relative humidity of airflows (Values = Average ± SD). 
Relative humidity % EF % FPF MMAD GSD 
(%RH)  < 5.8 < 3.3 (µm)  
51 64.6 ± 7.3 85.2 ± 3.3 48.8 ± 6.6 2.2 ± 0.3 2.4 
82 36.6 ± 2.1 86.4 ± 3.6 50.8 ± 2.8 2.1 ± 0.1 2.0 
 




Figure 3.7 The distribution of NC-Bud deposited on the cascade impactor when applied through 
an endotracheal tube (ID = 5.0 mm) at a flow rate of 30.0 L/min at different humidity of 
airflows. 
 
3.3.4 Powder performance using a novel inhaler 
Most dry powder inhalers (DPIs) were not designed for use with patients on mechanical 
ventilation. In order to apply dry powder technology to ventilated patients efficiently, DPIs 
should fit with the connections of the ventilator circuit. Here, a novel device was designed for 
this purpose. The novel inhaler was compared to the Monodose® inhaler (Figure 3.8). The 
resistance of the device is an important parameter that should be considered when designing a 
new inhaler. The resistance and the design of the inhaler can determine the efficiency of drug 
delivery 113,174. The specific flow resistance of the device is related to the pressure drop across 
the device and the volumetric flow rate as follows: 
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where R is the specific flow resistance, Q is the volumetric flow rate and ΔP is the pressure drop 
across the device 153. Based on the resistance, dry powder inhalers can be categorized into three 
groups; low, medium, and high resistance devices 90,156. The resistance of the device determines 
the turbulence of the airflow within the device. A high resistance inhaler such as the Inhalator 
Ingelheim® should generate higher turbulence, often resulting in higher %FPF compared to a 
medium resistance inhaler (Cyclohaler®, Diskhaler®) or a low resistance inhaler (Rotahaler®).  
 
Figure 3.8 Schematic diagrams of (A) the Monodose® inhaler, (B) the novel device, (C) the 
Monodose® inhaler connected to the mechanical ventilator circuit, and (D) the novel device 
connected to the mechanical ventilator circuit. 
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Besides the resistance of the device, the flow rate has an influence on the turbulence 
across the device. The inhalers should, therefore, be tested at the proper flow rate. Some 
recommended that inhalers should be tested at flow rates of 30 L/min, 60 L/min and 90-100 
L/min for high, medium and low resistance devices, respectively 90. Other studies reported that 
devices with different specific resistances can generate the same FPF if they are operated at a 
specific flow rate and using the same formulation 156. Thus, both device resistance and flow rate 
are critical.  
Moreover, the different patterns of turbulent airflow through the device depend on the 
internal geometry of the device. The effect of device design on the FPF of drug delivered was 
reported 156. For example, a study of aerosol performance delivered using medium resistance 
devices (Diskhaler® and Cyclohaler®) at different flow rates showed the same FPF at 60 L/min 
and different FPF at 30 L/min. Cyclohaler® was less sensitive to flow rate in the terms of FPF 
compared to Diskhaler®. The FPF of drug substantially decreased from the Diskhaler® at 30 
L/min 156. The authors suggested that the preferred device should generate a higher turbulence at 
low flow rate so that a high FPF could be obtained.  
The pressure drop across a device should be investigated when designing a new device. A 
pressure drop ranging from 2.9 – 16.0 kPa was reported for patients with varied lung disease 
states 175. From the United States Pharmacopeia (USP) standard, DPIs have to test at a constant 
inspiratory volume of 4 L and a constant pressure drop of 4 kPa 176. A study of relationships 
between the percent of relative de-agglomeration (%RD) of drug powder and the pressure drop 
in different inhalers showed that the Monodose® had the best %RD at the 4 kPa pressure drop. 
The report suggested that the Monodose® was the most efficient device compared to Rotahaler® 
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and Handihaler®, however, the relationship was different with different drug powders175. Here, 
the novel device had resistance of 0.0514 kPa0.5L-1min whereas the Monodose® was 0.018 
kPa0.5L-1min. The resistance of the novel device was significantly higher than the Monodose®. 
The NC-Bud aerosol was applied via the novel device through a 5.0 mm endotracheal 
tube at a flow rate of 30 L/min. The sine wave form and an inspiration volume of 2.5 L were 
used as before. The MMAD of NC-Bud when applied via the new inhaler was 1.7 ± 0.1 
compared to 2.2 ± 0.3 when applied via the Monodose®. The %EF of NC-Bud when applied via 
the novel device or Monodose® inhaler were not significantly different (p<0.05). The GSD of 
both experiments was around 2.3 to 2.4. (Table 3.5, Figure 3.9). Although the powder 
performance was not dramatically improved when applying the novel device, the novel device 
provided the convenience of a direct fit with the ventilator and the endotracheal tube 
connections.  
Table 3.5 Cascade impaction results of NC-Bud when applying through an endotracheal tube 
(ID = 5.0 mm) via different devices (Values = Average ± SD). 
Device % EF % FPF MMAD GSD 
   < 5.8 < 3.3 (µm)  
Monodose® inhaler 64.6 ± 7.3 85.2 ± 3.3 48.8 ± 6.6 2.2 ± 0.3 2.4 
Novel device 68.0 ± 6.2 89.6 ± 0.7 60.0 ± 1.5 1.7 ± 0.1 2.3 
 




Figure 3.9 The distribution of NC-Bud deposited on the cascade impactor when applied through 
an endotracheal tube (ID = 5.0 mm) at a flow rate of 30.0 L/min via different inhalers. 
 
3.3.5 Effect of inhalation cycles on powder performance 
To ensure that NC-Bud formulations emptied from the capsule, three inspiration cycles 
were applied. The data were then compared to the data when one inspiration cycle was applied. 
The aerosol was applied via the new inhaler through a 5.0 mm endotracheal tube. A flow rate of 
30 L/min, an inspiration volume of 2.5 L and the sine wave form inspiration pattern were 
controlled by the ventilator. The result showed the same performance of NC-Bud formulation 
when either one inspiration or three inspiration cycles was applied. The MMAD was the same 
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Table 3.6 Cascade impaction results of NC-Bud when applying through an endotracheal tube 
(ID = 5.0 mm) via the novel device. (Values = Average ± SD). 
Number of % EF % FPF MMAD GSD 
inspiration cycles  < 5.8 < 3.3 (µm)  
1-time 68.0 ± 6.2 89.6 ± 0.7 59.9 ± 1.5 1.7 ± 0.1 2.3 
3-times 72.9 ± 4.7 86.8 ± 1.9 58.9 ± 2.8 1.7 ± 0.1 2.5 
 
 
Figure 3.10 The distribution of NC-Bud deposited on the cascade impactor when applied 
through an endotracheal tube (ID = 5.0 mm) at a flow rate of 30.0 L/min with different 
inspiration cycles. 
 
As discuss previously, the capsule emptying time depended on the size of the capsule 
hole more than the size of the capsule 170. An optimal range of the capsule hole of  1.00 to 2.38 
mm was suggested for delivering high FPF with minimal impaction loss 171. A study found that 
the capsule with one hole of 1.5 mm can be emptied in 0.8 ± 0.05 seconds at a flow rate of 60 
L/min 170. Here, capsules with two holes of 1.5 mm were used to deliver NC-Bud formulations at 
a flow rate of 30 L/min. A 2.5 L inspiratory volume was applied for one cycle, so the inspiration 
time for one cycle equaled 5 seconds. Although, the ventilator flow rate was only 30 L/min, one 
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may suspect that, the capsule should be emptied in the first half of the first inspiration cycle. The 
remaining time of the inspiration cycle and the delayed time before the next cycle represent the 
time that powders can travel through and deposit in the cascade impactor. Since the data showed 
the same powder performance of NC-Bud for either one or three cycles, it can be deduced that 
NC-Bud also completely deposited within the cascade impactor before the next inspiration cycle 
started. 
3.3.6 Effect of tube diameter on powder performance 
The tube diameter can play a role in drug delivery efficiency in ventilated patients. For 
liquid formulations, larger diameter tubes are often preferred to small ones. Some studies 
reported that a reduction of the inner diameter of endotracheal tubes (5 to 7.5 mm) decreased 
aerosol delivery 79,146. NC-Bud formulations were previously delivered through different 
endotracheal tubes. The MMAD of NC-Bud powders actually decreased with a decrease in 
tubing diameter  154.  
Airflow in a tube can be categorized into three types; laminar, transient or turbulent. 
These types of airflows are described by the Reynolds number (Re). Re represents the 
relationship between the inertial forces and viscous force as follows154: 
                (Eq. 3.2) 
where ρ is the density of air (1.20 kg/m3 at 20◦C), ν is the linear velocity (m/s), d is the diameter 
of the tube (m), µ is the dynamic viscosity of air [1.81× 10−5 kg/(m.s) at 20◦C], Q is the 
volumetric flow rate (m3/s), and A is the tube cross-sectional area (m2). Laminar flow and 
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turbulent flow are typically observed at Re less than 2100 and Re more than 4000, respectively. 
Flow in the transient region (2100 < Re < 4000), can have laminar or turbulent character147. 
The NC-Bud aerosol was again delivered using a ventilator combined with the novel 
device. The flow rate of 30 L/min was applied. NC-Bud was applied through four different 
diameter tubes with inner diameters of 3.0, 5.0, 6.5 or 8.0 mm. NC-Bud showed smaller MMAD 
when applied through the catheter tube (3.0 mm ID) compared to endotracheal tubes (5.0, 6.5 
and 8.0 mm ID). The %FPF<5.8 was not significantly different (p<0.05), however, the %FPF<3.3 
of NC-Bud applied through the catheter tube was higher than the other tubes. The %EF of NC-
Bud was lower in the catheter tube compared to 6.5 and 8.0 mm endotracheal tubes but was not 
different when compared to the 5.0 mm tube. (Table 3.7, Figure 3.11).   
Table 3.7 Cascade impaction results of NC-Bud when applying through an endotracheal tube 
(ID = 5.0, 6.5, 8.0 mm) and a catheter tube (ID = 3.0 mm) via the novel device (Values = 
Average ± SD). 
Tube size % EF % FPF MMAD GSD 
(mm)  < 5.8 < 3.3 (µm)  
3.0 68.0 ± 3.2 90.8 ± 1.8 82.3 ± 2.8 0.9 ± 0.0 2.1 
5.0 68.0 ± 6.2 89.6 ± 0.7 59.9 ± 1.5 1.7 ± 0.1 2.3 
6.5 77.9 ± 2.3 89.2 ± 2.8 65.9 ± 6.6 1.4 ± 0.3 2.6 
8.0 78.2 ± 5.2 89.1 ± 2.5 63.9 ± 3.0 1.5 ± 0.1 2.6 
 




Figure 3.11 The distribution of NC-Bud deposited on the cascade impactor when applied 
through catheters and endotracheal tubes with different diameters at a flow rate of 30.0 L/min.  
 
The Re has an inverse relationship with diameter (d). The calculated Re values of 3.0, 
5.0, 6.0, and 8.0 mm tubes were 14067, 8440, 6492, and 5275, respectively. Although all of these 
are in the turbulent regime (Re>4000), the smallest ID tube had a very high Re compared to the 
other tubes. The higher turbulent flow corresponded to higher shear force in the airflow, 
probably improving de-agglomeration of the drug powders.   
3.3.7 Powder performance using a ventilation bag 
A ventilation bag was also used to provide the inspiration airflow and compared to 
ventilator using the same experimental conditions as described above. The %EF of NC-Bud was 
not significantly different when either the ventilator or the ventilation bag was used. The 
ventilator can provide a higher flow rate compared to the ventilator bag, resulting in a slightly 
higher %FPF of NC-Bud. A peak flow rate of approximately 23.0 L/min was measured for the 
ventilator bag. Consistently, the data showed a smaller MMAD (p<0.05) on the ventilator as well 
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(Table 3.8); however, the overall performance of NC-Bud was almost the same when using the 
ventilator or the ventilation bag (Figure 3.12).  
Table 3.8 Cascade impaction results of NC-Bud when applying through endotracheal tube (ID = 
5.0 mm) comparing between the ventilator and the ventilator bag. (Values = Average ± SD). 
Airflow supply % EF % FPF MMAD GSD 
   < 5.8 < 3.3 (µm)  
Ventilator 68.0 ± 6.2 89.6 ± 0.7 60.0 ± 1.5 1.7 ± 0.1 2.3 
Ventilator bag 63.9 ± 0.7 84.4 ± 1.4 49.2 ± 2.5 2.2 ± 0.1 2.4 
 
 
Figure 3.12 The distribution of NC-Bud deposited on the cascade impactor when applied 
through an endotracheal tube (ID = 5.0 mm) comparing between the ventilator and the ventilator 
bag.  
 
Other studies conducted using the ventilation bag confirmed the trends found when using 
the ventilator as the air source. Applying three cycles of inhalation using the ventilation bag 
showed a %EF was not different from a single inhalation (p<0.05) (Table 3.9). However, 
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multiple inhalation cycles resulted in a shift of the distribution towards a smaller MMAD 
(p<0.05) (Figure 3.13).  
Table 3.9 Cascade impaction results of NC-Bud when applying through an endotracheal tube 
(ID = 5.0 mm) via the novel device. The ventilator bag was used as the air source (Values = 
Average ± SD). 
Number of % EF % FPF MMAD GSD 
inspiration cycles  < 5.8 < 3.3 (µm)  
1-time 63.9 ± 0.7 84.4 ± 1.4 49.2 ± 2.5 2.2 ± 0.1 2.4 
3-times 68.6 ± 9.0 89.3 ± 1.8 63.6 ± 1.8 1.4 ± 0.1 2.6 
 
 
Figure 3.13 The distribution of NC-Bud deposited on the cascade impactor when applied 
through an endotracheal tube (ID = 5.0 mm) at a flow rate of 23 L/min. The ventilator bag was 
used as the air source. 
 
NC-Bud was also applied through different diameter endotracheal or catheter tubes (3.0, 
5.0 and 6.5 mm). As observed in ventilator experiments, larger diameter tubes provided a higher 
%EF of NC-Bud. The distribution of the NC-Bud shifted towards a smaller MMAD when 
applied through the smaller diameter tubes, especially the catheter tube (Table 3.10, Figure 3.14).   
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Table 3.10 Cascade impaction results of NC-Bud when applying via the novel device through an 
endotracheal tube (ID = 5.0, 6.5 mm) and a catheter tube. The ventilator bag was used as the air 
source (Values = Average ± SD). 
Tube size % EF % FPF MMAD GSD 
(mm)  < 5.8 < 3.3 (µm)  
3.0 54.6 ± 2.6 92.0 ± 2.1 77.6 ± 2.2 1.1 ± 0.0 2.1 
5.0 63.9 ± 0.7 84.4 ± 1.4 49.2 ± 2.5 2.2 ± 0.1 2.4 
6.5 74.3 ± 4.5 86.0 ± 3.1 52.9 ± 1.4 1.9 ± 0.1 2.5 
 
 
Figure 3.14 The distribution of NC-Bud deposited on the cascade impactor when applied 
through catheters and endotracheal tubes with different diameters. The ventilator bag was used as 









 NanoCluster budesonide (NC-Bud) dramatically improved aerosol performance 
compared to stock budesonide when delivered using a ventilator. Parameters controlled by the 
ventilator such as inspiration pattern and inspiratory volume, did not affect the performance of 
NC-Bud formulations. Volumetric flow rates in the range of 20 to 40 L/min also did not change 
the powder performance. Higher humidity in the ventilator circuit, however, decreased the 
percent emitted fraction although the fine particle fraction was not significantly changed. A 
novel device was preferred to the Monodose® due to the convenience of connecting with the 
ventilator and endotracheal tubing while maintaining efficient aerosol delivery. Studies using a 
ventilation bag were consistent but slightly different from the ventilator, probably due to the 
better inspiratory controls of the ventilator. NanoCluster technology combined with a new device 













1. Ari A, Fink JB 2010. Factors affecting bronchodilator delivery in mechanically ventilated 
adults. Nursing in Critical Care  15(4):192-203. 
2. Dhand R 2007. Inhalation therapy in invasive and noninvasive mechanical ventilation. 
Current opinion in critical care  13(1):27. 
3. Dolovich MB, Dhand R 2011. Aerosol drug delivery: developments in device design and 
clinical use. The Lancet  377(9770):1032-1045. 
4. Everard ML, Devadason SG, Le Souef PN 1996. In vitro assessment of drug delivery 
through an endotracheal tube using a dry powder inhaler delivery system. Thorax  51(1):75-77. 
5. Martonen TB, Smyth HD, Isaacs KK, Burton RT 2005. Issues in drug delivery: concepts 
and practice. Respiratory care  50(9):1228-1252. 
6. Pornputtapitak W, El-­‐gendy N, Berkland C 2011. Nanocluster budesonide formulations 
enhance drug delivery through endotracheal tubes. Journal of Pharmaceutical Sciences. 
7. Labiris NR, Dolovich MB 2003. Pulmonary drug delivery. Part II: the role of inhalant 
delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. 
British journal of clinical pharmacology  56(6):600-612. 
8. El-Gendy N, Gorman E, Munson E, Berkland C 2009. Budesonide nanoparticle 
agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci  98(8):2731-2746. 
9. Srichana T, Martin G, Marriott C 1998. Dry powder inhalers: the influence of device 
resistance and powder formulation on drug and lactose deposition in vitro. European Journal of 
Pharmaceutical Sciences  7(1):73-80. 
10. El-Gendy N, Selvam P, Soni P, Berkland C 2012. Development of budesonide 
nanocluster dry powder aerosols: Preformulation. Journal of Pharmaceutical Sciences  
101(9):3434-3444. 
11. Sassoon CSH, Foster GT 2001. Patient-ventilator asynchrony. Current opinion in critical 
care  7(1):28. 
12. Haas CF, Bauser KA 2012. Advanced Ventilator Modes and Techniques. Critical Care 
Nursing Quarterly  35(1):27. 
13. Georgopoulos D, Prinianakis G, Kondili E 2006. Bedside waveforms interpretation as a 
tool to identify patient-ventilator asynchronies. Intensive care medicine  32(1):34-47. 
14. Bowton DL, Hite RD 2011. 2.3 Ventilator mechanics. Practical Guide to Mechanical 
Ventilation:133. 
15. Hess DR, Dillman C, Kacmarek RM 2003. In vitro evaluation of aerosol bronchodilator 
delivery during mechanical ventilation: pressure-control vs. volume control ventilation. Intensive 
care medicine  29(7):1145-1150. 
16. Fink JB, Dhand R, Duarte AG, Jenne JW, Tobin MJ 1996. Aerosol delivery from a 
metered-dose inhaler during mechanical ventilation. An in vitro model. American journal of 
respiratory and critical care medicine  154(2):382-387. 
17. Mouloudi E, Prinianakis G, Kondili E, Georgopoulos D 2000. Bronchodilator delivery by 
metered-dose inhaler in mechanically ventilated COPD patients: influence of flow pattern. 
European Respiratory Journal  16(2):263-268. 
18. EVERARD ML 2000. CFC transition: the Emperor's new clothes. Each class of drug 
deserves a delivery system that meets its own requirements. Thorax  55(10):811. 
	   	  
99	  
	  
19. Newman S, Busse W 2002. Evolution of dry powder inhaler design, formulation, and 
performance. Respiratory medicine  96(5):293-304. 
20. Lenney J, Innes J, Crompton G 2000. Inappropriate inhaler use: assessment of use and 
patient preference of seven inhalation devices. Respiratory medicine  94(5):496-500. 
21. Ross DL, Schultz RK 1996. Effect of inhalation flow rate on the dosing characteristics of 
dry powder inhaler (DPI) and metered dose inhaler (MDI) products. Journal of aerosol medicine  
9(2):215-226. 
22. Behara SRB, Kippax P, Larson I, Morton DAV, Stewart P 2011. Kinetics of emitted 
mass--A study with three dry powder inhaler devices. Chemical Engineering Science. 
23. Coates MS, Chan HK, Fletcher DF, Raper JA 2005. Influence of air flow on the 
performance of a dry powder inhaler using computational and experimental analyses. 
Pharmaceutical research  22(9):1445-1453. 
24. Broeders M, Molema J, Vermue N, Folgering HTM 2001. Peak inspiratory flow rate and 
slope of the inhalation profiles in dry powder inhalers. European Respiratory Journal  18(5):780-
783. 
25. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR 
2005. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic 
obstructive pulmonary disease. American journal of respiratory and critical care medicine  
171(6):591-597. 
26. Coates MS, Fletcher DF, Chan HK, Raper JA 2005. The role of capsule on the 
performance of a dry powder inhaler using computational and experimental analyses. 
Pharmaceutical research  22(6):923-932. 
27. Chew NYK, Chan HK, Bagster DF, Mukhraiya J 2002. Characterization of 
pharmaceutical powder inhalers: estimation of energy input for powder dispersion and effect of 
capsule device configuration. Journal of Aerosol Science  33(7):999-1008. 
28. Chavan V, Dalby R 2002. Novel system to investigate the effects of inhaled volume and 
rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler. 
The AAPS Journal  4(2):7-12. 
29. Fink JB, Dhand R, Grychowski J, Fahey PJ, Tobin MJ 1999. Reconciling in vitro and in 
vivo measurements of aerosol delivery from a metered-dose inhaler during mechanical 
ventilation and defining efficiency-enhancing factors. American journal of respiratory and 
critical care medicine  159(1):63-68. 
30. Miller DD, Amin MM, Palmer LB, Shah AR, Smaldone GC 2003. Aerosol delivery and 
modern mechanical ventilation. American journal of respiratory and critical care medicine  
168(10):1205-1209. 
31. Zhu K, Tan RBH, Kiong Ng W, Shen S, Zhou Q, Heng PWS 2008. Analysis of the 
influence of relative humidity on the moisture sorption of particles and the aerosolization process 
in a dry powder inhaler. Journal of Aerosol Science  39(6):510-524. 
32. Chew NYK, Chan HK 2002. The role of particle properties in pharmaceutical powder 
inhalation formulations. Journal of Aerosol Medicine  15(3):325-330. 
33. Minne A, Boireau H, Horta MJ, Vanbever R 2008. Optimization of the aerosolization 
properties of an inhalation dry powder based on selection of excipients. European Journal of 
Pharmaceutics and Biopharmaceutics  70(3):839-844. 
34. Dunbar CA, Hickey AJ, Holzner P 1998. Dispersion and characterization of 
pharmaceutical dry powder aerosols. Kona  16:7-45. 
	   	  
100	  
	  
35. Amirav I, Newhouse MT, Mansour Y 2005. Measurement of peak inspiratory flow with 
in-­‐check dial device to simulate low-­‐resistance (Diskus) and high-­‐resistance (Turbohaler) dry 
powder inhalers in children with asthma. Pediatric pulmonology  39(5):447-451. 
36. Van Der Palen J 2003. Peak inspiratory flow through Diskus and Turbuhaler, measured 
by means of a peak inspiratory flow meter (In-Check DIAL®). Respiratory medicine  97(3):285-
289. 
37. Behara SRB, Larson I, Kippax P, Stewart P, Morton DAV 2012. Insight into pressure 
drop dependent efficiencies of dry powder inhalers. European Journal of Pharmaceutical 
Sciences. 
38. BYRON PR 1998. United States Pharmacopeia Recommendations for the Testing of 
Inhalers. Journal of aerosol medicine  11(s1):11-12. 
39. Takaya T, Takeyama K, Takiguchi M 2002. The efficiency of 2-agonist delivery through 
tracheal tubes with the metered-dose inhaler: an in vitro study. Journal of anesthesia  16(4):284-
288. 
40. Louey MD, Van Oort M, Hickey AJ 2006. Standardized entrainment tubes for the 






























NanoCluster itraconazole formulations provide a potential 












Drug nanoparticle formulations can be created by two approaches: bottom-up processes 
and top-down processes. Bottom-up processes such as precipitation builds up particles from the 
molecular state whereas the top-down processes such as milling breaks down large micron-sized 
particles into smaller particles1. In both processes, the large surface area of particles increases 
free energy of the particles. To reduce the free energy, smaller particles generated during 
processing tend to agglomerate together, and, potentially, crystalline nuclei will dissolve and 
precipitate onto other particles via Ostwald ripening2. Excipients such as surfactants and 
viscosity modifiers have been used to minimize agglomeration, but few have attempted to 
actually control the agglomeration process.  
In previous studies, budesonide was used to explore the phenomenon of nanoparticle 
agglomeration to create particles known as “NanoClusters”. NanoCluster dry powder aerosols 
demonstrate a desirable microstructure for efficient lung deposition and nanostructure for rapid 
dissolution of poorly water-soluble drugs. Studies have shown that budesonide NanoClusters 
provided efficient aerosolization with a high fine particle fraction and faster dissolution when 
compared to the stock micronized powder3. The success of NanoCluster technology encouraged 
the development of other inhaled drug formulations.  
Itraconazole (ITZ), a triazole antifungal agent, is a poorly water-soluble drug that has 
been explored as an inhaled therapeutic. The solubility of this drug in water is less than 1 µg/ml, 
across pH values from 1 – 12.74. ITZ has a broad spectrum of activity including Aspergillus 
species5. ITZ interferes in sterol biosynthesis in fungal cell membrane by inhibiting cytochrome 
P450 of the fungi, leading to cell death4. ITZ is orally administered for treatment of fungal 
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infections such as allergic bronchopulmonary aspergillosis (ABPA)6. Oral formulations must be 
given in high doses to achieve effective concentrations in the lungs. One study showed a partial 
but significant improvement of pulmonary function when patients were treated with oral ITZ for 
1 year7. Oral ITZ significantly improved clinical symptoms and reduced the mean dose of oral 
glucocorticoids required in patients with ABPA. Poor oral bioavailability and variable absorption 
of oral solutions limit ITZ to a second or third line treatment option. Absolute oral bioavailability 
of the oral capsule is 55% in the fed state and 40% lower in the fasted state8. Moreover, 
hydroxypropyl-β-cyclodextrin often used in the oral solution can cause gastrointestinal toxicity 
in patients9. 
 Since invasive aspergillosis primarily occurs in immunocompromised patients via 
inhalation of conidia into the lungs, the treatment of this fungal infection has been a focus for 
pulmonary drug delivery. Delivery of aerosolized ITZ to the lung tissue offers local treatment 
and prophylaxis against invasive aspergillosis at the primary site of infection in the lungs. 
Aerosolized ITZ can minimize systemic side effects, and eliminate the need for formulation with 
cyclodextrin. In vivo studies showed prolonged survival, high lung tissue concentrations, and low 
systemic exposure of aerosolized nanostructured ITZ formulations compared to commercially 
available ITZ oral solution10. A study showed the lung tissue concentration increased nearly 10 
times when ITZ was administered by inhalation compared to the oral route in a mouse model11. 
The ITZ administered as an aerosol significantly enhanced the survival of mice infected with 
Aspergillus fumigatus and achieved greater ratios of lung:serum drug concentration compared to 
the orally dosed ITZ compositions. High and sustained lung tissue concentrations were achieved 
while serum levels were maintained above the minimum lethal concentration (MLC) of A. 
fumigatus. Researchers mentioned that the high and sustained lung concentrations of inhaled ITZ 
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demonstrated effective local delivery to prevent fungal spore germination, growth, and 
dissemination of the fungus from the lung to the body12.  
 Although an inhaled formulation of ITZ has not been available to enable local treatment 
of aspergillosis, inhalation of aerosolized ITZ in the form of a nanosuspension has been studied 
in vivo13. More, recently, an ITZ dry powder was prepared and studied in vitro. Researchers 
reported the fine particle fraction (FPF) of amorphous ITZ was 16-47% when investigated using 
a multi-stage liquid impinger14. The variation of the percent FPF and percent of the emitted dose 
depended on excipients that were used in the formulation. Here, ITZ NanoCluster formulations 
were created via wet milling without using any excipients. The formulations obtained by wet 
milling (top-down process) were compared to formulations that were prepared by precipitation 
methods (bottom-up processes) and to stock itraconazole. The physicochemical properties and 
aerosol performance of different ITZ NanoClusters suggested an optimized top-down process 
might be the preferred process. 
4.2 Materials and methods 
4.2.1 Materials 
Itraconazole was purchased from Sigma Chemicals Co. (St. Louis, MO). Methanol, 
ethanol and methylene chloride were purchased through Fisher Scientific. Double-distilled water 








4.2.2.1 Itraconazole formulations (ITZ) prepared by precipitation methods  
NanoCluster suspensions of itraconazole were prepared using anti-solvent precipitation. 
Solutions of the drug in 1,3-dioxolane were prepared at concentrations of 0.4% (w/v). ITZ 
solution (5 ml) was directly injected into water at a rate of 5 mL/min using ultrasonication 
(probe-type sonicator, Fisher Scientific, Sonic Dismembrator) at amplitude of 30% in an ice bath 
or alternatively using homogenization (probe-type homogenizer, Tissue tearor, Biospec Products, 
Inc.) at 25,000 rpm. Suspensions were analyzed by dynamic light scattering. All measurements 
were performed in triplicate. After precipitation, the collected suspension was frozen at -80ºC 
and lyophilized for ~36 hours to remove all appreciable water content.  
4.2.2.2 Itraconazole formulations (ITZ) prepared by wet milling  
Itraconazole formulations (ITZ) were prepared by milling 1 gram of micronized 
itraconazole in 300 mL of 10%EtOH. The suspension was collected at 0.5, 1, and 2 hours milling 
time. A Netzsch MiniCer Media Mill was operated using YTZ® grinding media (0.2 mm, Tosoh 
Corp., Tokyo, Japan) under an agitation speed of 2004 rpm. Particle size of the suspensions was 
determined by dynamic light scattering (Brookhaven Instruments Corp., ZetaPALS, Holtsville, 
NY) at different time intervals during the milling process. After milling, the collected suspension 
was frozen at -80ºC and lyophilized for ~36 hours to remove all appreciable water content 
(VirTis Feezemobile-12XL, The Virtis Company,Gardiner, New York).  
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4.2.2.3 Aerosol characterization 
The aerodynamic characteristics of itraconazole (ITZ) formulations were determined 
using an Andersen Cascade Impactor (ACI) (Tisch Environmental, Inc., Village of Cleves, OH). 
Approximately 5 mg of each powder was filled in a capsule (gelatin type, size 3, generously 
provided from Capsugel, NJ, USA). Powder was introduced to the cascade impactor via a 
Monodose® inhaler (a Plastiape Monodose Inhaler RS01 Model 7) at ~90 L/min for 2.6 seconds 
or at ~30 L/min for 8.0 seconds. Cut-off particle aerodynamic diameters at 90 L/min for each 
stage of the impactor were: stage 0 (8.0 µm), stage 1 (6.5 µm), stage 2 (5.2 µm), stage 3 (3.3 
µm), stage 4 (2.1 µm), stage 5 (1.1 µm), stage 6 (0.7 µm), stage 7 (0.4 µm), and filter (0.0 µm). 
Cut-off particle aerodynamic diameters at 30 L/min for each stage of the impactor were: stage 0 
(9.0 µm), stage 1 (5.8 µm), stage 2 (4.7 µm), stage 3 (3.3 µm), stage 4 (2.1 µm), stage 5 (1.1 
µm), stage 6 (0.7 µm), stage 7 (0.4 µm), and filter (0.0 µm). 
Dry powders deposited on each stage of the impactor were quantified by the difference in 
weight of the plate on each stage before and after running the experiment. All experiments were 
performed under controlled conditions (21 ± 2 °C, 50 - 55% RH) in triplicate. The emitted dose 
(ED) was defined as the mass of drug collected from all stages of ACI. The emitted fraction (EF) 
was determined as the percent of the emitted dose divided by the initial mass delivered into the 
impactor. The fine particle fraction of the emitted dose (FPFED) was calculated as the percentage 
of aerosolized particles that have aerodynamic diameters below 6.5 µm (or 5.8 µm for 30 L/min) 
and the percentage of aerosolized particles that have aerodynamic diameters below 3.3 µm. The 
mass median aerodynamic diameter (MMAD) was determined at the 50th percentile of the 
cumulative mass distribution curve. Geometric standard deviation (GSD) was calculated as the 
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square root of the ratio of diameters at the percentile of 84.13% and 15.87% of the cumulative 
distribution. The percent emitted fraction (%EF), fine particle fractions of the emitted dose 
(FPFED), mass median aerodynamic diameter (MMAD), and geometric standard deviation (GSD) 
were calculated as previously reported15.  
4.2.2.4 Evaluation of particle size and morphology by scanning electron microscopy (SEM) 
The size and morphology of the formulated itraconazole powders were evaluated using 
an LEO 1550 field emission scanning electron microscope and compared to that of stock 
itraconazole powders.  Prior to imaging, the samples were sputter-coated with gold for thickness 
of 30 nm. 
4.2.2.5 Thermal analysis 
ITZ formulations were investigated by differential scanning calorimetry (DSC) (Q100 
Universal V4.3A; TA Instruments, New Castle, Delaware). Accurately weighed portions (2–3 
mg) of the lyophilized dry mass was sealed and placed in hermetic aluminum pans and heated at 
a constant rate of 10 ◦C/min over a temperature range of 40–300 ◦C for ITZ formulations. An 
inert atmosphere was maintained by purging with nitrogen at 50 mL/min. For thermal 
gravimetric analysis (TGA), samples weighing 5±2 mg were scanned at a rate of 10 ◦C/min with 
a nitrogen flow rate of 40 mL/min. 
4.2.2.6 Powder x-ray diffraction (PXRD)  
The crystallinity of the dried powders was determined by using powder x-ray diffraction (PXRD). 
PXRD was performed by using a monochromated CuKa radiation (l= 1.54178 Å) on a Bruker Proteum 
Diffraction System equipped with Helios multilayer optics, an APEX II CCD detector or a Platinum 135 
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CCD detector and a Bruker MicroStar microfocus rotating anode x-ray source operating at 45 kV and 60 
mA.  The powder sample was suspended in Paratone N oil then loaded on a nylon loop.  The loop was 
then loaded on the goniometer where either 3 or 2, 180° 10 minute scans (based on the detector) were 
taken using the Bruker Apex2 V2010.3-0 software package.  Scans were taken at 30°, 60° and 90° with 
the detector 50.0 mm away.  The patterns were analyzed using the Bruker EVA powder diffraction 
software package version 13.0  
4.2.2.7 High-performance liquid chromatography analysis 
The chemical stability of ITZ during processing was determined by using a Kromasil C8 
column (4.6 × 150 mm2, 5 µm). A mixture of methanol (MeOH) and 0.5% ammonium acetate 
(in water) in the ratio of 80/20 was used as mobile phase. The system was operated at a flow rate 
of 0.8 mL/min and the injection volume was 30 µL. Samples were monitored at a wavelength of 
261 nm. Itraconazole peak appeared at a retention time of around 6.6 min.  
4.2.2.8 Statistical analysis 
The results were presented as the mean and the significant differences were evaluated 
using Prism 4 GraphPad Software and assessed by one-way ANOVA followed by Tukey’s 
Multiple Comparison Test. One-tailed unpaired t-test was used for assessing the differences. All 
tests were evaluated at a level of confidence of p<0.05.  
4.3 Result and discussion 
4.3.1 Formulation of itraconazole (ITZ)   
In dry powder formulations, specific excipients are often required to achieve the desired 
aerosol properties. Inhaled excipients should be chemically and physically stable and harmless 
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on the respiratory tract. The number of authorized inactive ingredients, however, is quite limited 
and documentation of the safety profile of potential excipients for pulmonary administration is 
usually incomplete16. The lack of acceptable excipients can hinder formulation approaches, 
especially when attempting to develop aerosols of poorly water-soluble drugs. Therefore, 
engineering the drug itself has become attractive for developing inhaled drugs. Here, 
itraconazole (ITZ) was formulated without using any excipients. The ITZ formulations were 
prepared by two approaches: solvent precipitation (bottom-up method) and wet milling (top-
down method).  
4.3.1.1 Anti-solvent precipitation 
Many anti-solvent precipitation techniques have the same principles. The main steps 
consist of local supersaturation, nucleation, solute diffusion and particle growth17. In other 
words, nanoparticles are generated during mixing of solution and anti-solvent. When the drug 
concentration in the mixture is supersaturated, nucleation occurs and is followed by particle 
growth and agglomeration18. The nucleation and particle growth depend on the level of 
supersaturation. Thorat et.al. suggested that rapid and high supersaturation was the main driving 
force for precipitation18. If supersaturation is attained at a slow rate, the metastable zone is 
crossed very slowly, resulting in large crystals due to the dominance of particle growth. 
Conversely, if supersaturation is attained rapidly, the metastable zone is also crossed rapidly, 
resulting in small particles due to the dominance of nucleation in the precipitation process19,20. 
Therefore, particle formation depends on the speed of supersaturation that is partially controlled 
by the mixing process.  
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In order to enhance nucleation and suppress particle growth, rapid micro-mixing is 
normally used to generate particles, leading to ‘ultrafine’ nanoparticles21. Sufficient micro-
mixing can provide a uniform growth and a narrow particle size distribution. Rigorous micro-
mixing can be achieved in various ways such as anti-solvent precipitation, high-gravity 
controlled precipitation, supercritical fluid (SCF) technology, flash nanoprecipitation, and 
sonoprecipitation21.  
Sonoprecipitation is a method of precipitation that uses ultrasound to facilitate micro-
mixing. Many studies reported a decrease of mixing time when precipitation occurred under 
ultrasound22,23. One study showed that ultrasound provided more than 10 times higher mixing 
rate compared to mechanical stirring24. Ultrasound creates bubbles by generating alternate cycles 
of compression and rarefaction within a liquid. The critical size of bubbles then collapse 
(cavitation process)25. Ultrasonic waves can cause faster and fairly uniform nucleation 
throughout the sonicated volume, leading to smaller and more uniform-sized particles. 
Ultrasound effects supersaturated system by inducing high supersaturation and decreasing 
metastable zone width due to the higher mixing rate, resulting in faster nucleation and 
precipitation of smaller particles21,25,26. Ultrasound can also reduce agglomeration of particles by 






















Figure 4.1 SEM images of (A) ITZ as received, (B) milled ITZ, (C) ITZ (sonication) and (D) 
ITZ (homogenization) (Scale bar equals 1 µm). 
Itraconazole NanoClusters were prepared by anti-solvent precipitation using sonication or 
homogenization. Factors such as drug concentration, solvent type, rate of injection, 
homogenization speed, and amplitude of sonication were varied to optimize the precipitation 
conditions. Scanning electron microscopy (SEM) images showed different morphology of drug 
particles depending on the precipitation process (Figure 4.1). The size of particles decreased 
compared to ITZ as received. Consistently, increasing ultrasound power led to smaller 
particles21. Nevertheless, DSC thermograms of precipitated ITZ formulations showed an 
(A) (B) (A) 
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amorphous state in formulations prepared using sonication or using homogenization (Figure 4.2). 
The amorphous character of ITZ formulations was confirmed by PXRD (Figure 4.3).  
 
Figure 4.2 DSC profile of ITZ prepared by precipitation compared to ITZ as received. 
 
Figure 4.3 PXRD pattern of ITZ formulation. 




A study by Dalvi and Dave28 also found that precipitated itraconazole showed amorphous 
character due to high nucleation rates and rapid precipitation of itraconazole particles. They 
mentioned that hydrophobic molecules such as ITZ had a higher supersaturation compared to 
moderately water-soluble molecules due to a very low equilibrium solubility in anti-solvent-
solvent mixture. The nucleation rate is, therefore, always higher. Other researchers also indicated 
limitations of sonoprecipitation for drug nanoparticles21. Sonoprecipitation was reported to work 
better for production of amorphous nanoparticles although it has also been successfully used for 
preparing micron-size particles of drugs29,30. Although the amorphous state of drug particles may 
increase the dissolution rate14,31, amorphous forms can crystallize with time and the physical 
properties of the drug particles may change32. 
4.3.1.2 Wet milling 
Although there are many different mills, ball mills and jet mills are normally used for 
milling drug to a particle size range of 1–5 µm for inclusion in dry powder aerosol formulation16. 
Wet milling, another top-down method, was chosen to prepare ITZ NanoClusters. Wet milling is 
a process that utilizes milling media to grind a suspension of insoluble drug. The milling media 
can be ceramic33, metallic, glass34 or highly crosslinked polystyrene resin-coated beads35,36. 
Drugs are dispersed into medium, usually water with surfactant and possibly a viscosity 
modifier. The movement of the milling media generates shear force and pulverizes the drug 
particles, leading to size reduction down to 100nm or less37,38. The wet milling technique can be 
scaled up without batch-to-batch variation37. Wet milling processes have been used to produce a 
few FDA approved drugs38. Several inhaled drugs such as beclomethasone dipropionate, 
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budesonide, fluticasone propionate, and itraconazole39 have been investigated. Itraconazole, for 
example, was studied in the form of nanosuspension in order to use with pMDI40.  
In this study, itraconazole (ITZ) NanoClusters were formulated in the form of dry powder 
for DPI applications. Micronized itraconazole as received was milled using different conditions 
and durations. Milling time depends on many factors such as the surfactant content (none in this 
case), hardness of the drug, viscosity, temperature, energy input, and size of the milling media35. 
The milling time can be less than 30 minutes to hours or several days41. Several studies showed 
that processing time could be very lengthy for itraconazole. For example, Yang et. al. 
itraconazole was milled for 10 days under nitrogen gas to get amorphous ITZ33 while Tam et. al. 
spent 2 weeks to mill ITZ in water to get spherical nanoparticles40. Here, ITZ suspensions were 
collected at milling times of 0.5, 1, and 2 hours.  
SEM images showed changes in drug morphology and particle sizes of ITZ after milling 
process (Figure 4.1). The smaller particles and higher porosity of ITZ NanoClusters compared to 
micronized itraconazole as received increased the surface area. The SEM images showed 
structures consistent with agglomeration of nanoparticles to form NanoClusters, which would be 
expected to reduce the free energy of nanoparticles.  
ITZ powders milled for larger times showed increasing amorphous state on the DSC 
thermograms (Figure 4.4). The peak of recrystallization appeared at around 80-90 °C. The degree 
of amorphousness of ITZ was confirmed by x-ray diffraction patterns (Figure 4.5). It is 
noteworthy that x-ray diffraction patterns of ITZ prepared by precipitation were different from x-
ray diffraction patterns of ITZ formulation prepared by milling technique. This difference of x-
ray diffraction patterns indicated different polymorphs of ITZ powders. A study mentioned that 
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polymorphism might be controlled by solvent selection although metastable polymorphs are 
sometimes produced in preference to the thermodynamic form25.  
 
Figure 4.4 DSC thermogram of ITZ milled in water for different durations.  




Figure 4.5 PXRD pattern of ITZ milled in water for different durations. 
 
4.3.1.3 Characterization of aerosolized ITZ formulations  
The aerosolization of NanoCluster itraconazole formulations was assessed by cascade 
impaction. ITZ powders were delivered via Monodose® inhaler at flow rate of 90 L/min for 2.6 
seconds. The aerosolization efficiency was quantified as the percent emitted fraction (%EF), the 
percent fine particle fraction (%FPF), and mass median aerodynamic diameter (MMAD). The 
aerosol performance of ITZ NanoClusters prepared by milling in water was assessed. The 
particle size distributions of ITZ formulations were not significantly different (p<0.05) when ITZ 
suspension was collected at milling times of 0.5, 1, or 2 hours (Figure 4.6). Although the %EF 
was slightly lower when the powder was milled longer, the %FPF and MMAD of these powders 
were not different (p<0.05) (Table 4.1).  
	   	  
117	  
	  
Table 4.1 Cascade impaction of milled itraconazole at a flow rate of 90 L/min (Values = 
Average ± SD). 
Milling time % EF % FPF MMAD GSD 
(hour)   < 6.5 < 3.3 (µm)   
0.5 86.6 ± 6.5 93.8 ± 1.1 79.7 ± 1.7 0.9 ± 0.0 2.2 ± 0.1 
1 74.8 ± 11.4 91.1 ± 0.9 66.8 ± 3.3 1.3 ± 0.1 2.2 ± 0.2 
2 66.6 ± 3.2 97.5 ± 0.6 78.2 ± 3.8 1.0 ± 0.1 2.0 ± 0.1 
 
 
Figure 4.6 The distribution of ITZ milled in water for different durations (flow rate of 90 
L/min). 
 
Milled ITZ showed better aerosolization performance compared to ITZ as received and 
precipitated ITZ (Figure 4.7). The %EF of milled ITZ was 86.6 ± 6.5%, much higher than the 
%EF of precipitated ITZ (around 50-60%) and ITZ as received (44.4 ± 1.3%). Milled ITZ also 
showed the smallest MMAD of around 1 µm. The GSD of milled ITZ (around 2) was also 
smaller than the GSD of precipitated ITZ and ITZ as received, which were around 3 (Table 4.2). 
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Table 4.2 Cascade impaction of different itraconazole formulation at a flow rate of 90 L/min 
(Values = Average ± SD). 
Formulation % EF % FPF MMAD GSD 
    < 6.5 < 3.3 (µm)    
ITZ as received 44.4 ± 1.3 73.2 ± 1.2 47.5 ± 0.8 2.3 ± 0.0 3.1 ± 0.0 
Milled ITZ* 86.6 ± 6.5 93.8 ± 1.1 79.7 ± 1.7 0.9 ± 0.0 2.2 ± 0.1 
ITZ(sonication) 50.2 ± 7.3 75.6 ± 3.7 57.7 ± 5.9 1.5 ± 0.4 3.5 ± 0.2 
ITZ(homogenization) 58.1 ± 5.3 75.0 ± 1.4 48.2 ± 8.9 2.2 ± 0.5 3.1 ± 0.1 
      * 30 minutes milled ITZ. 
 
Figure 4.7 The distribution of different ITZ formulations (flow rate of 90 L/min). 
4.3.2 Effect of dispersion solvent 
4.3.2.1 Characteristic of powders 
 Although milled ITZ showed better aerosolization performance compared to precipitated 
or stock ITZ, DSC thermograms showed that milled ITZ contained some of amorphous 
characteristics. According to our studies and some studies in literature25, a dispersion solvent 
may play a significant role in the physical characteristics of formulated powders. If 
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polymorphism or amorphousness can be controlled by solvent selection25, a suitable dispersion 
solvent should affect a preference towards amorphous or crystalline ITZ powders.  
 
Figure 4.8 DSC thermogram of ITZ milled in different dispersion solvent. 
 Itraconazole is insoluble in water and very slightly soluble in alcohols. Alcohols such as 
ethanol (EtOH) are known to affect on wettability and dispersibility of a poorly water-soluble 
drug during milling. Since the solvent has an influence on the polymorphism or 
amorphousness25, adding ethanol to the  dispersion expected to affect the physical character of 
ITZ NonaClusters. Micronized ITZ as received was, therefore, milled in water, 5% EtOH and 
10% EtOH. The DSC thermogram showed crystalline character of powders when ITZ was milled 
in media that contained ethanol (Figure 4.8). The crystalline state was confirmed by PXRD 
patterns. Moreover, the DSC profiles and PXRD patterns of ITZ milled in 10% EtOH did not 
show amorphous character across mill times of 2 hours (Figure 4.9, 4.10).  




Figure 4.9 DSC thermogram of ITZ milled in 10% EtOH for different durations. 
 
 
Figure 4.10 PXRD pattern of ITZ milled in 10% EtOH for different durations. 
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The amorphous state of a drug formulation is important and should be considered when 
formulating drug powders. Although amorphous phases can improve the dissolution and 
bioavailability of poorly soluble compounds33, they can be thermodynamically unstable and 
change to a more stable state over time42. The presence of amorphous phases, even in small 
quantities, may affect the physical and chemical stability of pharmaceutical products43. 
Recrystallization depends on both molecular mobility and configurational entropy of the drug44. 
Molecules with lower configurational entropies require less mobility for spontaneous 
crystallization. Therefore, drugs with high configurational entropy barriers and low molecular 
mobility (i.e. crystals) should exhibit greater physical stability compared to amorphous forms45. 
4.3.2.2 Aerosolization performance of ITZ milled in water/ethanol mixtures 
 ITZ milled for half an hour in water, 5% EtOH, or 10% EtOH were compared to ITZ as 
received (Figure 4.11). The distribution of milled ITZ shifted toward a smaller MMAD 
compared to stock ITZ. The MMAD was decreased from 2.3 to 1.0 after milling (Table 4.3). At 
the same time, the %EF of milled ITZ formulations was two times higher than the %EF of ITZ 
as received. The %FPF of milled ITZ formulations was around 90-95% at a cut-off diameter of 
6.5 µm and around 75-80% at a cut-off diameter of 3.3 µm. The GSD of milled ITZ formulations 
was also smaller than the GSD of ITZ as received. Although ITZ milled in different percentages 
of ethanol did not show a difference in aerosolization performance, as discuss previously, the 
ethanol helped to control the crystallinity of drug during the milling process.  
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Table 4.3 Cascade impaction of itraconazole prepared by milling for 30 minutes in different 
media at a flow rate of 90 L/min (Values = Average ± SD). 
Formulation % EF % FPF MMAD GSD 
   < 6.5 < 3.3 (µm)   
ITZ (water) 86.6 ± 6.5 93.8 ± 1.1 79.7 ± 1.7 0.9 ± 0.0 2.2 ± 0.1 
ITZ (5% EtOH) 82.5 ± 3.9 94.5 ± 2.5 78.0 ± 3.4 1.0 ± 0.1 2.2 ± 0.2 
ITZ (10% EtOH) 80.3 ± 10.7 91.8 ± 1.2 75.8 ± 0.8 1.2 ± 0.1 2.0 ± 0.1 
 
 
Figure 4.11 The distribution of ITZ milled for 30 minutes in different dispersion solvent (flow 
rate of 90 L/min). 
 
4.3.3 Effect of flow rate on aerosolization performance 
 Dry powder formulations are delivered to patients via dry powder inhalers (DPIs). Each 
DPI has a specific resistance across the device, leading to different required flow rates to 
disperse the powder. DPIs on the market are normally breath-actuated devices. The efficiency of 
dry powder drug delivery using these devices depends on the patient’s inspiration efforts. During 
inhalation, flowing air will generate shear force across the device, resulting in dispersion of drug 
	   	  
123	  
	  
powders46. Besides drug formulations, therefore, flow rate across the DPIs should be 
investigated.   
In general, powder dispersion increases when the flow rate is increased from 15 to 90 
L/min47. High flow rate increases agglomerate break-up into smaller particles, resulting in a shift 
of the distribution towards smaller sizes. In our previous study, budesonide NanoCluster size 
distribution shifted toward a smaller MMAD when a higher flow rate was applied15.  
ITZ formulations were introduced to a cascade impactor via a Monodose® inhaler. 
Changing the flow rate affected both ITZ as received and the milled ITZ formulation. The 
MMAD of ITZ as received decreased from 5.5 ± 0.6 µm to 2.3 ± 0.0 µm while the MMAD of 
milled ITZ decreased from 3.7 ± 0.4 µm to 1.2 ± 0.1 µm when the volumetric flow rate was 
increased from 30 L/min to 90 L/min (Table 4.4). The particle size distribution of ITZ powders 
was also shifted toward smaller MMAD when flow was applied at 90 L/min compared to 30 
L/min (Figure 4.12). Increasing flow rate had a slight effect on the %EF of ITZ as received (from 
33.7 ± 8.6 µm to 44.4 ± 1.3 µm); however, it did not show any effect on the %EF of milled ITZ 
(from 79.2 ± 0.6 µm to 80.3 ± 10.7 µm). Furthermore, it is worth noting that the %FPF of milled 
ITZ increased substantially when the flow rate was 90 L/min. The %FPF<3.3 of milled ITZ 
increased from 21.4 ± 2.0 % to 75.8 ± 0.8 % compared to %FPF<3.3 of ITZ as received (from 
20.9 ± 3.1 % to 47.5 ± 0.8 %). Milled ITZ in the form of NanoClusters was easy to 
deagglomerate into small particles, leading to a large fine particle fraction. On the contrary, a 
high flow rate can increase the dispersion of ITZ as received but it cannot dramatically change 
the size of the particles due to the solid form of particles. 
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Table 4.4 Cascade impaction of itraconazole at different flow rates (Values = Average ± SD). 
Flow 
rate Formulation % EF % FPF MMAD GSD 




33.7 ± 8.6 46.4 ± 6.2 - 20.9 ± 3.1 5.5 ± 0.6 2.2 ± 0.2 




44.4 ± 1.3 - 73.2 ± 1.2 47.5 ± 0.8 2.3 ± 0.0 3.1 ± 0.0 
 Milled ITZ* 80.3 ± 10.7 - 91.8 ± 1.2 75.8 ± 0.8 1.2 ± 0.1 2.0 ± 0.1 
* 30 minutes milled ITZ.  
 
Figure 4.12 The distribution of ITZ when applied at different flow rates. 
The effect of flow rate normally plays a greater role for DPIs that have low dispersion 
efficiencies. A study demonstrated the different effect on powder performance at any flow rate 
when tested via a low dispersion efficiency inhaler and a high dispersion efficiency inhaler48. 
Using the same particles, the low dispersion efficiency inhaler required higher shear force to 
maximize powder delivery. They also found flow dependence for the smaller powder (2.7 µm) 
but less dependence on larger particles (5 µm) when using the low dispersion efficiency inhaler. 
30 L/min 90 L/min 
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Conversely, the FPF of 5 µm particles was decreased when applied via the higher dispersion 
efficiency inhaler at the same flow rate used for the low dispersion efficiency inhaler. The 
Monodose® inhaler is a low resistance DPI device that was designed for use at flow rate of 90 
L/min.  
4.4 Conclusion 
Itraconazole (ITZ) NanoCluster formulations prepared by a wet-milling technique 
showed better aerosol performance compared to micronized ITZ as received and ITZ 
NanoCluster formulations prepared by precipitation methods. An amorphous state appeared, 
however, when ITZ was milled in water for half an hour or more. Adding a small amount of 
ethanol during milling played an important role in dictating the crystallinity of drug particles. 
ITZ milled in 10% EtOH maintained the crystalline character of ITZ even during a 2 hour 
milling time. Milled ITZ NanoClusters also showed substantially improved of aerosol 
performance when tested at a high inspiration flow rate. In conclusion, ITZ NanoCluster 
formulations represent a potential engineered particle approach for inhalation drug development, 
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NanoCluster technology provides an effective approach for engineering dry powder 
aerosols especially for inhalation. Particles in the size range of 1-5 µm are desired for efficient 
deposition in the lungs. NanoClusters are agglomerated nanoparticles that combine the 
advantages of nanoparticles and microparticles. Nanoparticles increase dissolution rate of drug 
powders as a result of high surface area while microparticle structure provides a suitable size for 
aerosolization and deposition along the respiratory tract.  
 For patients on mechanical ventilation, liquid formulations have been used for routine 
treatment. Liquid formulations perform poorly with variable delivery due to in efficient aerosol 
conduction or condensation of wet aerosols in the endotracheal tube. Dry powder technology, 
was investigated as an alternative approach for inhalation drug delivery in these patients. Dry 
powder formulations have been primarily used in non-ventilated patients. Dry powder inhalers 
that are available on the market are also not designed for use with ventilated patients, leading to 
inefficient drug delivery.  
 In this thesis, we formulated NanoClusters of inhaled drugs and developed a dry powder 
inhaler for use with mechanical ventilation. In chapter 2, budesonide NanoClusters were 
prepared by a wet-milling technique and delivery through an endotracheal tube was investigated. 
We found that budesonide NanoClusters showed better aerosolization performance compared to 
stock micronized budesonide and Pulmicort Flexhaler powder. Budesonide NanoCluster powders 
showed a high emitted fraction and a high percentage of fine particles were achieved when 
NanoClusters were applied through the endotracheal tube. Comparing, a Teflon tube and a 
commercial (PVC) endotracheal tube did not show any difference. Other parameters such as 
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volumetric flow rate, tube diameter and humidity were also studied. A higher volumetric flow 
rate and smaller tube diameter substantial increased the fine particle fraction and particle size 
distribution shifted toward smaller MMAD.   
NanoCluster budesonide formulations efficiently navigated through the endotracheal 
tube, which is a major barrier for liquid formulations. The success of introducing NanoClusters 
though the endotracheal tube led to a study of aerosol performance of this formulation driven by 
mechanical ventilation in chapter 3. The study showed that the NanoCluster budesonide 
formulation dramatically improved aerosol performance delivery compared to stock budesonide. 
Parameters such as inspiration pattern, inspiration volume and volumetric flow rate did not affect 
the aerosolization performance of budesonide NanoClusters when delivered through 
endotracheal tubes using the ventilator. It is noteworthy that only the volumetric flow rate in the 
range of 20 – 40 L/min was studied because of backpressure limitations on the ventilator. The 
ventilator shuts down automatically when applied at very high flow rate to protect patients from 
injury.  
As mentioned previously, DPIs on the market have not been designed for use with the 
ventilation system. In this study, a novel inhaler was developed and compared with a modified 
Monodose® inhaler. The study also demonstrated that a novel device could be connected 
directly to the ventilator and endotracheal tubing while maintaining efficient aerosol delivery. 
Using a ventilation bag instead of the ventilator remarked consistency of particle size 
distribution for either air source. The ventilator should provide better inspiratory control 
compared to the ventilation bag, yet our results suggested inconsistency to the air source. 
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NanoCluster technology combined with a new device, therefore, offers an effective drug delivery 
option for patients on mechanical ventilation. 
The better aerosolization performance of budesonide NanoClusters compared to stock 
budesonide and Pulmicort Flexhaler powders (chapter 1) represented an effective engineered 
particle approach, therefore, this technology was applied to formulate other inhaled drugs such as 
itraconazole (chapter 4). For treatment of local disease in the lung, inhalation of itraconazole is 
preferred to oral administration because of low bioavailability in the gastrointestinal tract. In this 
chapter, itraconazole NanoClusters were prepared by wet-milling and precipitation methods. 
Itraconazole NanoClusters formulated by wet milling showed better aerosolization performance 
than precipitated itraconazole formulations and stock itraconazole. Moreover, wet-milling 
maintained the crystalline character of itraconazole when stock itraconazole was milled in 10% 
ethanol whereas the precipitation process generated amorphous itraconazole. Milled itraconazole 
NanoClusters, therefore, represent an effective drug formulation for inhalation compared to 
precipitated itraconazole and stock itraconazole due to the better aerosol performance and 
crystallinity of the drug formulation.  
5.2 Future directions 
The next steps of dry powder drug development can be divided into three main areas. The 
first area is formulation development. NanoCluster technology is worthy of exploration for other 
inhaled drugs. Although NanoCluster technology was useful to develop budesonide and 
itraconazole powder, the processing conditions should be optimized for each drug. Each drug has 
different properties such as hardness and brittleness. For example, low grinding speed and short 
milling time were preferred in order to diminish the formation of amorphous material during 
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milling of itraconazole and to optimize the aerosol properties of dry powder formulation. 
Conversely, optimal budesonide milling used higher grinding speed and longer times.  
The second area is device design for use with the ventilator. Since dry powder inhalers 
have not been routine used for patients on mechanical ventilation, we designed a novel inhaler to 
fit the connection and endotracheal tube. Although our device performed effectively, 
modification of the design should be continued in order to optimize efficiency. Moreover, the 
new device has to be modified for use with rat, rabbit or other animal model.  
Last but not least, NanoCluster formulations should be studied both in vitro on human 
ventilators and in vivo in animal ventilators. Budesonide NanoClusters were successfully 
delivered on a ventilator system that connected to a cascade impactor. The next step for 
budesonide NanoClusters is animal studies. The device should be modified to deliver budesonide 
NanoClusters to the animals such as rats or rabbits. The ventilation system for any animal has to 
be studied and optimized. Parameters such as the dose of the drug powder, delivery time, and 
volumetric flow rates have to be adjusted to suit the animal. For furthering itraconazole 
NanoCluster formulations, the next step is an in vitro mechanical ventilation study. An 
exploration of ventilator parameters should be performed. Then, an animal study should be 
considered. 
 
 
 
